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Abstract
The Concise Guide to PHARMACOLOGY 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available),
plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise
Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time
record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13884/full. Voltage-gated ion channels are one of the eight
major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ligand-gated ion channels, other ion channels, nuclear hormone receptors, catalytic
receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for
further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16
and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature Committee of the Union of Basic and Clinical Pharmacology
(NC-IUPHAR), therefore, providing ofﬁcial IUPHAR classiﬁcation and nomenclature for human drug targets, where appropriate.
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CatSper and Two-Pore channels
Voltage-gated ion channels → CatSper and Two-Pore channels
Overview: CatSper channels (CatSper1-4, nomenclature as
agreed by NC-IUPHAR [69]) are putative 6TM, voltage-gated,
calcium permeant channels that are presumed to assemble as a
tetramer of α-like subunits and mediate the current ICatSper [193].
Inmammals, CatSper subunits are structurallymost closely related
to individual domains of voltage-activated calcium channels (Cav)
[349]. CatSper1 [349], CatSper2 [341] and CatSpers 3 and 4 [173,
245, 338], in commonwith a putative 2TM auxiliary CatSperβ pro-
tein [242] and two putative 1TM associated CatSperγ and CatSperδ
proteins [64, 434], are restricted to the testis and localised to the
principle piece of sperm tail.
Two-pore channels (TPCs) are structurally related to CatSpers,
CaVs and NaVs. TPCs have a 2x6TM structure with twice the num-
ber of TMs of CatSpers and half that of CaVs. There are three an-
imal TPCs (TPC1-TPC3). Humans have TPC1 and TPC2, but not
TPC3. TPC1 and TPC2 are localized in endosomes and lysosomes
[43]. TPC3 is also found on the plasma membrane and forms
a voltage-activated, non-inactivating Na+ channel [44]. All the
three TPCs are Na+-selective under whole-cell or whole-organelle
patch clamp recording [45, 46, 457]. The channels may also
conduct Ca2+ [272].
Nomenclature CatSper1 CatSper2 CatSper3 CatSper4
HGNC, UniProt CATSPER1, Q8NEC5 CATSPER2, Q96P56 CATSPER3, Q86XQ3 CATSPER4, Q7RTX7
Activators CatSper1 is constitutively active, weakly facilitated by membrane
depolarisation, strongly augmented by intracellular alkalinisation. In
human, but not mouse, spermatozoa progesterone (EC50 ˜8 nM) also
potentiates the CatSper current (ICatSper) [239, 390]
– – –
Channel blockers ruthenium red (pIC50 5) [193] – Mouse, HC-056456 (pIC50 4.7) [50],
Cd2+ (pIC50 3.7) [193] – Mouse, Ni2+ (pIC50 3.5) [193] – Mouse
– – –
Selective channel blockers NNC55-0396 (pIC50 5.7) [-80mV – 80mV] [239, 390], mibefradil
(pIC50 4.4–4.5) [390]
– – –
Functional Characteristics Calcium selective ion channel (Ba2+>Ca2+Mg2+Na+);
quasilinear monovalent cation current in the absence of extracellular
divalent cations;
alkalinization shifts the voltage-dependence of activation towards
negative potentials [V½ @ pH 6.0 = +87 mV (mouse); V½ @ pH 7.5 =
+11mV (mouse) or pH 7.4 = +85 mV (human)]; required for ICatSper
and male fertility (mouse and human)
Required for ICatSper and male
fertility (mouse and human)
Required for ICatSper and male
fertility (mouse)
Required for ICatSper and male
fertility (mouse)
Searchable database: http://www.guidetopharmacology.org/index.jsp CatSper and Two-Pore channels S161
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Nomenclature TPC1 TPC2
HGNC, UniProt TPCN1, Q9ULQ1 TPCN2, Q8NHX9
Activators phosphatidyl (3,5) inositol bisphosphate (pEC50 6.5) [45] phosphatidyl (3,5) inositol bisphosphate (pEC50 6.4) [439]
Channel blockers verapamil (pIC50 4.6) [45], Cd2+ (pIC50 3.7) [45] verapamil (pIC50 5) [439]
Functional Characteristics Organelle voltage-gated Na+-selective channel (Na+K+Ca2+); Required for the generation of action
potential-like long depolarization in lysosomes. Voltage-dependence of activation is sensitive to luminal pH
(determined from lysosomal recordings). ψ1/2 @ pH4.6 = +91 mV; ψ1/2 @ pH6.5 = +2.6 mV. Maximum
activity requires PI(3,5)P2 and reduced [ATP]
Organelle voltage-independent Na+-selective channel
(Na+K+Ca2+). Sensitive to the levels of PI(3,5)P2. Activated
by decreases in [ATP] or depletion of extracellular amino acids
Comments: CatSper channel subunits expressed singly, or in
combination, fail to functionally express in heterologous expres-
sion systems [341, 349]. The properties of CatSper1 tabulated
above are derived from whole cell voltage-clamp recordings com-
paring currents endogenous to spermatozoa isolated from the
corpus epididymis of wild-type andCatsper1(-/-) mice [193] and also
mature human sperm [239, 390]. ICatSper is also undetectable
in the spermatozoa of Catsper2(-/-),Catsper3(-/-), Catsper4(-/-), or
CatSperδ (-/-) mice, and CatSper 1 associates with CatSper 2, 3, 4, β,
γ, and δ [64, 242, 338]. Moreover, targeted disruption of Catsper1,
2, 3, 4, or δ genes results in an identical phenotype in which
spermatozoa fail to exhibit the hyperactive movement (whip-
like ﬂagellar beats) necessary for penetration of the egg cumulus
and zona pellucida and subsequent fertilization. Such disruptions
are associated with a deﬁcit in alkalinization and depolarization-
evoked Ca2+ entry into spermatozoa [51, 64, 338]. Thus, it is
likely that the CatSper pore is formed by a heterotetramer of
CatSpers1-4 [338] in association with the auxiliary subunits (β,
γ, δ) that are also essential for function [64]. CatSper channels
are required for the increase in intracellular Ca2+ concentration
in sperm evoked by egg zona pellucida glycoproteins [457]. Mouse
and human sperm swim against the ﬂuid ﬂow and Ca2+ signal-
ing through CatSper is required for the rheotaxis [268]. In vivo,
CatSper1-null spermatozoa cannot ascend the female reproduc-
tive tracts efﬁciently [65, 151]. It has been shown that CatSper
channels form four linear Ca2+ signaling domains along the
ﬂagella, which orchestrate capacitation-associated tyrosine phos-
phorylation [65].The driving force for Ca2+ entry is principally
determined by a mildly outwardly rectifying K+ channel (KSper)
that, like CatSpers, is activated by intracellular alkalinization
[283]. Mouse KSper is encoded by mSlo3, a protein detected only
in testis [262, 283, 478]. In human sperm, such alkalinization
may result from the activation of Hv1, a proton channel [240].
Mutations in CatSpers are associated with syndromic and non-
syndromic male infertility [144]. In human ejaculated spermato-
zoa, progesterone (<50 nM) potentiates the CatSper current by
a non-genomic mechanism and acts synergistically with intracel-
lular alkalinisation [239, 390]. Sperm cells from infertile patients
with a deletion in CatSper2 gene lack ICatSper and the progesterone
response [375]. In addition, certain prostaglandins (e.g. PGF1α,
PGE1) also potentiate CatSper mediated currents [239, 390].
In human sperm, CatSper channels are also activated by various
small molecules including endocrine disrupting chemicals (EDC)
and proposed as a polymodal sensor [39, 39].
TPCs are the major Na+ conductance in lysosomes; knocking out
TPC1 and TPC2 eliminates the Na+ conductance and renders the
organelle’s membrane potential insensitive to changes in [Na+]
(31). The channels are regulated by luminal pH [45], PI(3,5)P2
[439], intracellular ATP and extracellular amino acids [46]. TPCs
are also involved in the NAADP-activated Ca2+ release from lyso-
somal Ca2+ stores [43, 272]. Mice lacking TPCs are viable but have
phenotypes including compromised lysosomal pH stability, re-
duced physical endurance [46], resistance to Ebola viral infection
[358] and fatty liver [124]. No major human disease-associated
TPC mutation has been reported.
Further reading on CatSper and Two-Pore channels
Clapham DE et al. (2005) International Union of Pharmacology. L. Nomenclature and structure-
function relationships of CatSper and two-pore channels. Pharmacol. Rev. 57: 451-4
[PMID:16382101]
Grimm C et al. (2017) Two-Pore Channels: Catalyzers of Endolysosomal Transport and Function.
Front Pharmacol 8: 45 [PMID:28223936]
Kintzer AF et al. (2017) On the Structure and Mechanism of Two-Pore Channels. FEBS J
[PMID:28656706]
Searchable database: http://www.guidetopharmacology.org/index.jsp CatSper and Two-Pore channels S162
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Cyclic nucleotide-regulated channels
Voltage-gated ion channels → Cyclic nucleotide-regulated channels
Overview: Cyclic nucleotide-gated (CNG) channels are respon-
sible for signalling in the primary sensory cells of the vertebrate
visual and olfactory systems. A standardised nomenclature
for CNG channels has been proposed by the NC-IUPHAR
subcommittee on voltage-gated ion channels [154].
CNG channels are voltage-independent cation channels formed as
tetramers. Each subunit has 6TM, with the pore-forming domain
between TM5 and TM6. CNG channels were ﬁrst found in rod
photoreceptors [107, 188], where light signals through rhodopsin
and transducin to stimulate phosphodiesterase and reduce intra-
cellular cyclic GMP level. This results in a closure of CNG chan-
nels and a reduced ‘dark current’. Similar channels were found in
the cilia of olfactory neurons [282] and the pineal gland [95]. The
cyclic nucleotides bind to a domain in the C terminus of the sub-
unit protein: other channels directly binding cyclic nucleotides
include HCN, eag and certain plant potassium channels.
Nomenclature CNGA1 CNGA2 CNGA3 CNGB3
HGNC, UniProt CNGA1, P29973 CNGA2, Q16280 CNGA3, Q16281 CNGB3, Q9NQW8
Activators cyclic GMP (EC50 ˜30 μM)  cyclic AMP cyclic GMP > cyclic AMP
(EC50 ˜1 μM)
cyclic GMP (EC50 ˜30 μM) 
cyclic AMP
–
Inhibitors – – L-(cis)-diltiazem (high afﬁnity binding
requires presence of CNGB subunits)
–
Channel blockers dequalinium (pIC50 6.7) [0mV] [355], L-(cis)-diltiazem (high
afﬁnity binding requires presence of CNGB subunits) (pKi 4)
[-80mV – 80mV] [58]
dequalinium (pIC50 5.6)
[0mV] [354]
– L-(cis)-diltiazem (Channel blocker
when CNGB3 coexpressed with
CNGA3) (pIC50 5.5) [0mV] [116] –
Mouse
Functional Characteristics γ = 25-30 pS
PCa/PNa = 3.1
γ = 35 pS
PCa/PNa = 6.8
γ = 40 pS
PCa/PNa = 10.9
–
Comments: CNGA1, CNGA2 and CNGA3 express functional channels as homomers. Three additional subunits CNGA4 (Q8IV77), CNGB1 (Q14028) and CNGB3 (Q9NQW8) do not, and are referred to
as auxiliary subunits. The subunit composition of the native channels is believed to be as follows. Rod: CNGA13/CNGB1a; Cone: CNGA32/CNGB32; Olfactory neurons: CNGA22/CNGA4/CNGB1b [323,
445, 480, 481, 483].
Searchable database: http://www.guidetopharmacology.org/index.jsp Cyclic nucleotide-regulated channels S163
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Hyperpolarisation-activated, cyclic nucleotide-gated
(HCN) channels
The hyperpolarisation-activated, cyclic nucleotide-gated (HCN)
channels are cation channels that are activated by hyperpolar-
isation at voltages negative to ˜-50 mV. The cyclic nucleotides
cyclic AMP and cyclic GMP directly activate the channels and
shift the activation curves of HCN channels to more positive volt-
ages, thereby enhancing channel activity. HCN channels underlie
pacemaker currents found in many excitable cells including car-
diac cells and neurons [92, 308]. In native cells, these currents
have a variety of names, such as Ih, Iq andIf. The four knownHCN
channels have six transmembrane domains and form tetramers.
It is believed that the channels can form heteromers with each
other, as has been shown for HCN1 and HCN4 [7]. A standard-
ised nomenclature for HCN channels has been proposed
by the NC-IUPHAR subcommittee on voltage-gated ion
channels [154].
Nomenclature HCN1 HCN2 HCN3 HCN4
HGNC, UniProt HCN1, O60741 HCN2, Q9UL51 HCN3, Q9P1Z3 HCN4, Q9Y3Q4
Activators cyclic AMP > cyclic GMP (both weak) cyclic AMP > cyclic GMP – cyclic AMP > cyclic GMP
Channel blockers ivabradine (pIC50 5.7) [384], ZD7288
(pIC50 4.7) [383], Cs+ (pIC50 3.7) [-40mV]
[383]
ivabradine (pIC50 5.6) [384] – Mouse,
ZD7288 (pIC50 4.4) [383], Cs+ (pIC50 3.7)
[-40mV] [383]
ivabradine (pIC50 5.7) [384], ZD7288
(pIC50 4.5) [383], Cs+ (pIC50 3.8) [-40mV]
[383]
ivabradine (pIC50 5.7) [384], ZD7288 (pIC50
4.7) [383], Cs+ (pIC50 3.8) [-40mV] [383]
Comments: HCN channels are permeable to both Na+ and K+ ions, with a Na+/K+ permeability ratio of about 0.2. Functionally, they differ from each other in terms of time constant of activation with
HCN1 the fastest, HCN4 the slowest and HCN2 and HCN3 intermediate. The compounds ZD7288 [37] and ivabradine [42] have proven useful in identifying and studying functional HCN channels in
native cells. Zatebradine and cilobradine are also useful blocking agents.
Further reading on Cyclic nucleotide-regulated channels
Herrmann S et al. (2015) HCN channels–modulators of cardiac and neuronal excitability. Int J Mol
Sci 16: 1429-47 [PMID:25580535]
Hofmann F et al. (2005) International Union of Pharmacology. LI. Nomenclature and structure-
function relationships of cyclic nucleotide-regulated channels. Pharmacol Rev 57: 455-62
[PMID:16382102]
Podda MV et al. (2014) New perspectives in cyclic nucleotide-mediated functions in the CNS:
the emerging role of cyclic nucleotide-gated (CNG) channels. Pﬂugers Arch 466: 1241-57
[PMID:24142069]
Tsantoulas C et al. (2016) HCN2 ion channels: basic science opens up possibilities for therapeutic
intervention in neuropathic pain. Biochem J 473: 2717-36 [PMID:27621481]
Potassium channels
Voltage-gated ion channels → Potassium channels
Overview: Activation of potassium channels regulates excitabil-
ity and can control the shape of the action potential waveform.
They are present in all cells within the body and can inﬂuence pro-
cesses as diverse as cognition, muscle contraction and hormone
secretion. Potassium channels are subdivided into families, based
on their structural and functional properties. The largest fam-
ily consists of potassium channels that activated by membrane
depolarization, with other families consisting of channels that
are either activated by a rise of intracellular calcium ions or are
constitutively active. A standardised nomenclature for potassium
channels has been proposed by the NC-IUPHAR subcommit-
tees on potassium channels [120, 135, 211, 444], which has
placed cloned channels into groups based on gene family and
structure of channels that exhibit 6, 4 or 2 transmembrane do-
mains (TM).
Searchable database: http://www.guidetopharmacology.org/index.jsp Potassium channels S164
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Calcium- and sodium-activated potassium channels
Voltage-gated ion channels → Potassium channels → Calcium- and sodium-activated potassium channels
Overview: The 6TM family of K channels comprises the voltage-gated KV subfamilies, including the KCNQ subfamily, the EAG subfamily (which includes herg channels), the Ca2+-activated Slo subfamily
(actually with 6 or 7TM) and the Ca2+- and Na+-activated SK subfamily (nomenclature as agreed by the NC-IUPHAR Subcommittee on Calcium- and sodium-activated potassium channels
[181]). As for the 2TM family, the pore-forming a subunits form tetramers and heteromeric channels may be formed within subfamilies (e.g. KV1.1 with KV1.2; KCNQ2 with KCNQ3).
Nomenclature KCa1.1 KCa2.1 KCa2.2 KCa2.3 KCa3.1
HGNC, UniProt KCNMA1, Q12791 KCNN1, Q92952 KCNN2, Q9H2S1 KCNN3, Q9UGI6 KCNN4, O15554
Activators NS004, NS1619 EBIO Concentration range: 2×10−3M
[-80mV] [320, 442], NS309
Concentration range:
3×10−8M-1×10−7M [-90mV] [388, 442]
NS309 (pEC50 6.2) Concentration
range: 3×10−8M-1×10−7M [319,
388, 442], EBIO (pEC50 3.3) [319,
442], EBIO (pEC50 3) Concentration
range: 2×10−3M [48, 320] – Rat
EBIO (pEC50 3.8) [442, 450],
NS309 Concentration range:
3×10−8M [388, 442]
NS309 (pEC50 8) [-90mV] [388,
442], SKA-121 (pEC50 7) [72],
EBIO (pEC50 4.1–4.5) [-100mV –
-50mV] [320, 394, 442]
Inhibitors paxilline (pKi 8.7) [0mV]
[360] – Mouse
UCL1684 (pIC50 9.1) [387, 442], apamin
(pIC50 7.9–8.5) [367, 385, 387]
UCL1684 (pIC50 9.6) [103, 442],
apamin (pKd 9.4) [180]
apamin (pIC50 7.9–9.1) [407,
450], UCL1684 (pIC50 8–9)
[103, 442]
TRAM-34 (pKd 7.6–8) [213, 456]
Channel blockers charybdotoxin, iberiotoxin,
tetraethylammonium
tetraethylammonium (pIC50 2.7) [442] tetraethylammonium (pIC50 2.7)
[442]
tetraethylammonium (pIC50
2.7) [442]
charybdotoxin (pIC50 7.6–8.7)
[171, 176]
Functional
Characteristics
Maxi KCa SKCa SKCa SKCa IKCa
Comments – The rat isoform does not form functional
channels when expressed alone in cell
lines. N- or C-terminal chimeric
constructs permit functional channels
that are insensitive to apamin [442].
Heteromeric channels are formed
between KCa2.1 and 2.2 subunits that
show intermediate sensitivity to apamin
[68].
– – –
Searchable database: http://www.guidetopharmacology.org/index.jsp Calcium- and sodium-activated potassium channels S165
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Nomenclature KNa1.1 KNa1.2 KCa5.1
HGNC, UniProt KCNT1, Q5JUK3 KCNT2, Q6UVM3 KCNU1, A8MYU2
Activators bithionol (pEC50 5–6) [470] – Rat, niclosamide (pEC50 5.5)
[32], loxapine (pEC50 5.4) [32]
niﬂumic acid (pEC50 8.7) [78, 115] –
Gating inhibitors bepridil (pIC50 5–6) [470] – Rat – –
Channel blockers quinidine (pIC50 4) [29, 470] – Rat Ba2+ (pIC50 3) [29], quinidine Concentration range:
1×10−3M [29] – Rat
quinidine Concentration range: 2×10−5M [404, 454]
– Mouse
Functional Characteristics KNa KNa Sperm pH-regulated K+ current, KSPER
Inwardly rectifying potassium channels
Voltage-gated ion channels → Potassium channels → Inwardly rectifying potassium channels
Overview: The 2TM domain family of K channels are also known as the inward-rectiﬁer K channel family. This family includes the strong inward-rectiﬁer K channels (Kir2.x) that are constitutively
active, the G-protein-activated inward-rectiﬁer K channels (Kir3.x) and the ATP-sensitive K channels (Kir6.x, which combine with sulphonylurea receptors (SUR1-3)). The pore-forming α subunits form
tetramers, and heteromeric channels may be formed within subfamilies (e.g. Kir3.2 with Kir3.3).
Nomenclature Kir1.1
HGNC, UniProt KCNJ1, P48048
Ion Selectivity and Conductance NH4+ [62pS] > K+ [38. pS] > Tl+ [21pS] > Rb+ [15pS] (Rat) [62, 150]
Channel blockers tertiapin-Q (pIC50 8.9) [175], Ba2+ (pIC50 2.3–4.2) Concentration range: 1×10−4M [voltage dependent 0mV – -100mV] [150, 484] – Rat, Cs+ (pIC50 2.9) [voltage
dependent -120mV] [484] – Rat
Functional Characteristics Kir1.1 is weakly inwardly rectifying, as compared to classical (strong) inward rectiﬁers.
Searchable database: http://www.guidetopharmacology.org/index.jsp Inwardly rectifying potassium channels S166
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(continued)
Nomenclature Kir2.1 Kir2.2 Kir2.3 Kir2.4
HGNC, UniProt KCNJ2, P63252 KCNJ12, Q14500 KCNJ4, P48050 KCNJ14, Q9UNX9
Endogenous activators PIP2 Concentration range:
1×10−5M-5×10−5M [-30mV] [158,
348, 379] – Mouse
– – –
Endogenous inhibitors – Intracellular Mg2+ (pIC50 5) [40mV] [469] – Intracellular Mg2+
Gating inhibitors – Ba2+ Concentration range: 5×10−5M [-150mV – -50mV]
[397] – Mouse, Cs+ Concentration range:
5×10−6M-5×10−5M [-150mV – -50mV] [397] – Mouse
– –
Endogenous channel blockers spermine (pKd 9.1) [voltage
dependent 40mV] [167, 471] –
Mouse, spermidine (pKd 8.1)
[voltage dependent 40mV] [471] –
Mouse, putrescine (pKd 5.1)
[voltage dependent 40mV] [167,
471] – Mouse, Intracellular Mg2+
(pKd 4.8) [voltage dependent
40mV] [471] – Mouse
– Intracellular Mg2+ (pKd 5)
[voltage dependent 50mV] [246],
putrescine Concentration range:
5×10−5M-1×10−3M [-80mV –
80mV] [246], spermidine
Concentration range:
2.5×10−5M-1×10−3M [-80mV –
80mV] [246], spermine
Concentration range:
5×10−5M-1×10−3M [-80mV –
80mV] [246]
Channel blockers Ba2+ (pKd 3.9–5.6) Concentration
range: 1×10−6M-1×10−4M
[voltage dependent 0mV – -80mV]
[6] – Mouse, Cs+ (pKd 1.3–4)
Concentration range:
3×10−5M-3×10−4M [voltage
dependent 0mV – -102mV] [3] –
Mouse
– Ba2+ (pIC50 5) Concentration
range: 3×10−6M-5×10−4M
[-60mV] [260, 335, 405], Cs+ (pKi
1.3–4.5) Concentration range:
3×10−6M-3×10−4M [0mV –
-130mV] [260]
Cs+ (pKd 3–4.1) [voltage dependent
-100mV – -60mV] [159], Ba2+ (pKd
3.3) [voltage dependent 0mV] [159]
Functional Characteristics IK1 in heart, ‘strong’
inward–rectiﬁer current
IK1 in heart, ‘strong’ inward–rectiﬁer current IK1 in heart, ‘strong’
inward–rectiﬁer current
IK1 in heart, ‘strong’
inward–rectiﬁer current
Comments Kir2.1 is also inhibited by
intracellular polyamines
Kir2.2 is also inhibited by intracellular polyamines Kir2.3 is also inhibited by
intracellular polyamines
Kir2.4 is also inhibited by
intracellular polyamines
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(continued)
Nomenclature Kir3.1 Kir3.2 Kir3.3 Kir3.4
HGNC, UniProt KCNJ3, P48549 KCNJ6, P48051 KCNJ9, Q92806 KCNJ5, P48544
Endogenous activators PIP2 (pKd 6.3) Concentration range: 5×10−5M
[physiological voltage] [158]
PIP2 (pKd 6.3) Concentration range:
5×10−5M [physiological voltage] [158]
PIP2 [145] PIP2 [20, 145]
Gating inhibitors – pimozide (Data obtained using Kir3.1/3.2
heteromer) (pEC50 5.5) [-70mV] [201] –
Mouse
– –
Channel blockers tertiapin-Q (Kir3.1/3.4; expression in Xenopus oocytes)
(pIC50 7.9) [174], Ba2+ (Kir3.1 expressed in Xenopus oocytes)
(pIC50 4.7) [80] – Rat
desipramine (Data obtained using
Kir3.1/3.2 heteromer) (pIC50 4.4) [-70mV]
[202] – Mouse
– tertiapin-Q
(Kir3.1/3.4) (pIC50
7.9) [174]
Functional Characteristics G protein-activated inward-rectiﬁer current G protein-activated inward-rectiﬁer current G protein-activated
inward-rectiﬁer current
G protein-activated
inward-rectiﬁer
current
Comments Kir3.1 is also activated by Gβγ. Kir3.1 is not functional alone.
The functional expression of Kir3.1 in Xenopus oocytes
requires coassembly with the endogenous Xenopus Kir3.5
subunit. The major functional assembly in the heart is the
Kir3.1/3.4 heteromultimer, while in the brain it is Kir3.1/3.2,
Kir3.1/3.3 and Kir3.2/3.3.
Kir3.2 is also activated by Gβγ. Kir3.2 forms
functional heteromers with Kir3.1/3.3.
Kir3.3 is also activated by Gβγ Kir3.4 is also
activated by Gβγ
Nomenclature Kir4.1 Kir4.2 Kir5.1
HGNC, UniProt KCNJ10, P78508 KCNJ15, Q99712 KCNJ16, Q9NPI9
Channel blockers Ba2+ Concentration range: 3×10−6M-1×10−3M [-160mV –
60mV] [205, 399, 403] – Rat, Cs+ Concentration range:
3×10−5M-3×10−4M [-160mV – 50mV] [399] – Rat
Ba2+ (Kir4.2 expressed in Xenopus oocytes) Concentration
range: 1×10−5M-1×10−4M [-120mV – 100mV] [318] –
Mouse, Cs+ (Kir4.2 expressed in Xenopus oocytes)
Concentration range: 1×10−5M-1×10−4M [-120mV –
100mV] [318] – Mouse
Ba2+ (Kir5.1 expressed with PSD-95) Concentration
range: 3×10−3M [-120mV – 20mV] [402] – Rat
Functional Characteristics Inward-rectiﬁer current Inward-rectiﬁer current Weakly inwardly rectifying
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Nomenclature Kir6.1 Kir6.2 Kir7.1
HGNC, UniProt KCNJ8, Q15842 KCNJ11, Q14654 KCNJ13, O60928
Associated subunits SUR1, SUR2A, SUR2B SUR1, SUR2A, SUR2B –
Activators cromakalim, diazoxide Concentration range: 2×10−4M
[-60mV] [466] – Mouse, minoxidil, nicorandil
Concentration range: 3×10−4M [-60mV – 60mV] [466] –
Mouse
diazoxide (pEC50 4.2) [physiological voltage] [162] –
Mouse, cromakalim Concentration range: 3×10−5M
[-60mV] [163] – Mouse, minoxidil, nicorandil
–
Inhibitors glibenclamide, tolbutamide glibenclamide, tolbutamide –
Channel blockers – – Ba2+ (pKi 3.2) [voltage dependent -100mV] [99, 210,
212, 311], Cs+ (pKi 1.6) [voltage dependent -100mV]
[99, 210, 311]
Functional Characteristics ATP-sensitive, inward-rectiﬁer current ATP-sensitive, inward-rectiﬁer current Inward-rectiﬁer current
Two P domain potassium channels
Voltage-gated ion channels → Potassium channels → Two P domain potassium channels
Overview: The 4TM family of K channels mediate many of the
background potassium currents observed in native cells. They are
open across the physiological voltage-range and are regulated by a
wide array of neurotransmitters and biochemical mediators. The
pore-forming α-subunit contains two pore loop (P) domains and
two subunits assemble to form one ion conduction pathway lined
by four P domains. It is important to note that single channels do
not have two pores but that each subunit has two P domains in its
primary sequence; hence the name two P domain, or K2P chan-
nels (and not two-pore channels). Some of the K2P subunits can
form heterodimers across subfamilies (e.g. K2P3.1 with K2P9.1).
The nomenclature of 4TM K channels in the literature is still a
mixture of IUPHAR and common names. The suggested division
into subfamilies, below, is based on similarities in both structural
and functional properties within subfamilies.
Nomenclature K2P1.1 K2P2.1 K2P3.1 K2P4.1
HGNC, UniProt KCNK1, O00180 KCNK2, O95069 KCNK3, O14649 KCNK4, Q9NYG8
Endogenous activators – arachidonic acid (studied at 1-10 μM)
(pEC50 5) [314]
– arachidonic acid (studied at 1-10
μM) [108]
Activators – chloroform (studied at 1-5 mM)
Concentration range: 8×10−3M [313],
halothane (studied at 1-5 mM) [313],
isoﬂurane (studied at 1-5 mM) [313]
halothane (studied at 1-10 mM) riluzole (studied at 1-100 μM) [97]
Channel blockers – – R-(+)-methanandamide (pIC50 ∼6.2) [257], anandamide
(pIC50 ∼6.2) [257]
–
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Nomenclature K2P1.1 K2P2.1 K2P3.1 K2P4.1
Functional Characteristics Background current Background current Background current Background current
Comments K2P1.1 is inhibited by acid pHo
external acidiﬁcation with a pKa ˜
6.7 [331]. K2P1 forms
heterodimers with K2P3 and K2P9
[332].
K2P2.1 is also activated by membrane
stretch, heat and acid pHi [256, 258].
K2P2 can heterodimerize with K2P4
[33] and K2P10 [228].
Knock-out of the kcnk3 gene leads to a prolonged QT
interval in mice [83] and disrupted development of the
adrenal cortex [143]. K2P3.1 is inhibited by acid pHo with
a pKa of 6.4 [247]. K2P3 forms heterodimers with K2P1
[332] and K2P9 [77].
K2P4 is activated by membrane
stretch [255], and increased
temperature ( ˜12 to 20-fold
between 17 and 40°C [183]) and
can heterodimerize with K2P2 [33].
Nomenclature K2P5.1 K2P6.1 K2P7.1 K2P9.1
HGNC, UniProt KCNK5, O95279 KCNK6, Q9Y257 KCNK7, Q9Y2U2 KCNK9, Q9NPC2
Activators – – – halothane (studied at 1-5 mM) [401]
Inhibitors – – – R-(+)-methanandamide (studied at 1-10 μM)
[343], anandamide (studied at 1-10 μM) [343]
Functional Characteristics Background current Unknown Unknown Background current
Comments K2P5.1 is activated by alkaline pHo [351]. Knockout of the kcnk5 gene
in mice is associated with metabolic acidosis, hyponatremia and
hypotension due to impaired bicarbonate handling in the kidney [441],
as well as deafness [55]. The T108P mutation is associated with Balkan
Endemic Nephropathy in humans [414].
– – K2P9.1 is also inhibited by acid pHo with a pKa of ˜
6 [343]. Imprinting of the KCNK9 gene is
associated with Birk Barel syndrome [18]. K2P9
can form heterodimers with K2P1 [332] or K2P3
[77].
Nomenclature K2P10.1 K2P12.1 K2P13.1 K2P15.1 K2P16.1 K2P17.1 K2P18.1
HGNC, UniProt KCNK10, P57789 KCNK12, Q9HB15 KCNK13,
Q9HB14
KCNK15,
Q9H427
KCNK16, Q96T55 KCNK17, Q96T54 KCNK18, Q7Z418
Endogenous activators arachidonic acid (studied at
1-10 μM) [225]
– – – – – –
Activators halothane (studied at 1-5
mM) [225]
– – – – – –
Endogenous inhibitors – – – – – – arachidonic acid (studied
at 10-50 μM) [361]
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Nomenclature K2P10.1 K2P12.1 K2P13.1 K2P15.1 K2P16.1 K2P17.1 K2P18.1
Inhibitors norﬂuoxetine (pIC50 5.1)
[189]
– halothane
(studied at ˜5
mM) [34]
– – – –
Functional Characteristics Background current Does not function as a
homodimer [342] but can
form a functional
heterodimer with K2P13
[34].
Background
current
Unknown Background current Background current Background current
Comments K2P10.1 is also activated by
membrane stretch [225]
and can heterodimerize
with K2P2 [228].
– Forms a
heterodimer
with K2P12
[34].
– K2P16.1 current is
increased by alkaline pHo
with a pKa of 7.8 [184].
K2P17.1 current is
increased by alkaline pHo
with a pKa of 8.8 [184].
A frame-shift mutation
(F139WfsX24) in the
KCNK18 gene, is
associated with migraine
with aura in humans
[214].
Comments: The K2P6, K2P7.1, K2P15.1 and K2P12.1 subtypes, when expressed in isolation, are nonfunctional. All 4TM channels are insensitive to the classical potassium channel blockers
tetraethylammonium and fampridine, but are blocked to varying degrees by Ba2+ ions.
Voltage-gated potassium channels
Voltage-gated ion channels → Potassium channels → Voltage-gated potassium channels
Overview: The 6TM family of K channels comprises the voltage-gated KV subfamilies, the EAG subfamily (which includes hERG channels), the Ca2+-activated Slo subfamily (actually with 7TM, termed
BK) and the Ca2+-activated SK subfamily. These channels possess a pore-forming α subunit that comprise tetramers of identical subunits (homomeric) or of different subunits (heteromeric). Heteromeric
channels can only be formed within subfamilies (e.g. Kv1.1 with Kv1.2; Kv7.2 with Kv7.3). The pharmacology largely reﬂects the subunit composition of the functional channel.
Nomenclature Kv1.1 Kv1.2 Kv1.3 Kv1.4
HGNC, UniProt KCNA1, Q09470 KCNA2, P16389 KCNA3, P22001 KCNA4, P22459
Associated subunits Kv1.2, Kv1.4, Kvβ1 and Kvβ2 [73] Kv1.1, Kv1.4, Kv β1 and Kv β2 [73] Kv1.1, Kv1.2, Kv1.4, Kv1.6 , Kv β1 and Kv
β2 [73]
Kv1.1, Kv1.2, Kvβ1 and Kvβ2 [73]
Channel blockers α-dendrotoxin (pEC50 7.7–9) [128, 160] –
Rat, margatoxin (pIC50 8.4) [19],
tetraethylammonium (pKd 3.5) [128] –
Mouse
margatoxin (pIC50 11.2) [19], α-dendrotoxin
(pIC50 7.8–9.4) [128, 160] – Rat, noxiustoxin
(pKd 8.7) [128] – Rat
margatoxin (pIC50 10–10.3) [113, 117],
noxiustoxin (pKd 9) [128] – Mouse,
maurotoxin (pIC50 6.8) [352],
tetraethylammonium (pKd 2) [128] –
Mouse
fampridine (pIC50 1.9) [391] – Rat
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Nomenclature Kv1.1 Kv1.2 Kv1.3 Kv1.4
Selective channel
blockers
– – correolide (pIC50 7.1) [106] –
Functional Characteristics KV KV KV KA
Comments – – Resistant to dendrotoxins Resistant to dendrotoxins
Nomenclature Kv1.5 Kv1.6 Kv1.7 Kv1.8
HGNC, UniProt KCNA5, P22460 KCNA6, P17658 KCNA7, Q96RP8 KCNA10, Q16322
Associated subunits Kv β1 and Kv β2 Kv β1 and Kv β2 Kv β1 and Kv β2 Kv β1 and Kv β2
Channel blockers fampridine (pIC50 4.3) [105] α-dendrotoxin (pIC50 7.7) [129],
tetraethylammonium (pIC50 2.2) [129]
noxiustoxin (pIC50 7.7) [182] – Mouse,
fampridine (pIC50 3.6) [182] – Mouse
fampridine (pIC50 2.8) [217]
Functional Characteristics Kv KV KV KV
Comments Resistant to external TEA – – –
Nomenclature Kv2.1 Kv2.2 Kv3.1 Kv3.2 Kv3.3 Kv3.4
HGNC, UniProt KCNB1, Q14721 KCNB2, Q92953 KCNC1, P48547 KCNC2, Q96PR1 KCNC3, Q14003 KCNC4, Q03721
Associated subunits Kv5.1, Kv6.1-6.4,
Kv8.1-8.2 and
Kv9.1-9.3
Kv5.1, Kv6.1-6.4, Kv8.1-8.2
and Kv9.1-9.3
– – – MiRP2 is an associated subunit
for Kv3.4
Channel blockers tetraethylammonium
(pIC50 2) [142] – Rat
fampridine (pIC50 2.8)
[363], tetraethylammonium
(pIC50 2.6) [363]
fampridine (pIC50 4.5) [128] –
Mouse, tetraethylammonium
(pIC50 3.7) [128] – Mouse
fampridine (pIC50 4.6) [233]
– Rat, tetraethylammonium
(pIC50 4.2) [233] – Rat
tetraethylammo-
nium (pIC50 3.9)
[419] – Rat
tetraethylammonium (pIC50
3.5) [350, 365] – Rat
Selective channel
blockers
– – – – – sea anemone toxin BDS-I
(pIC50 7.3) [93] – Rat
Functional Characteristics KV – KV KV KA KA
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Nomenclature Kv4.1 Kv4.2 Kv4.3
HGNC, UniProt KCND1, Q9NSA2 KCND2, Q9NZV8 KCND3, Q9UK17
Associated subunits KChIP 1-4, DP66, DPP10 KChIP 1-4, DPP6, DPP10, Kvβ1, NCS-1, Navβ1 KChIP 1-4, DPP6 and DPP10, MinK, MiRPs
Channel blockers fampridine (pIC50 2) [166] – –
Functional Characteristics KA KA KA
Nomenclature Kv5.1 Kv6.1 Kv6.2 Kv6.3 Kv6.4
HGNC, UniProt KCNF1, Q9H3M0 KCNG1, Q9UIX4 KCNG2, Q9UJ96 KCNG3, Q8TAE7 KCNG4, Q8TDN1
Nomenclature Kv7.1 Kv7.2 Kv7.3 Kv7.4 Kv7.5
HGNC, UniProt KCNQ1, P51787 KCNQ2, O43526 KCNQ3, O43525 KCNQ4, P56696 KCNQ5, Q9NR82
Activators – retigabine (pEC50 5.6) [406] retigabine (pEC50 6.2) [406] retigabine (pEC50 5.2) [406] retigabine (pEC50 5) [98]
Inhibitors XE991 (pKd 6.1) [436],
linopirdine (pIC50 4.4)
[302] – Mouse
XE991 (pIC50 6.2) [437],
linopirdine (pIC50 5.3) [437],
linopirdine (pIC50 5.4) [437] –
Rat
XE991 (pIC50 5.3) [396], linopirdine
(pIC50 4.9) [396],
linopirdine (pKd 4.8)
[224], XE991 (pIC50 4.2)
[364]
Channel blockers tetraethylammonium (pIC50
3.5–3.9) [136, 446]
– tetraethylammonium (pIC50 1.3) [13]
Functional Characteristics cardiac IK5 M current as a heteromer between
KV7.2 and KV7.3
M current as heteromeric
KV7.2/KV7.3 or KV7.3/KV7.5
– M current as heteromeric
KV7.3/KV7.5
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Nomenclature Kv8.1 Kv8.2 Kv9.1 Kv9.2 Kv9.3 Kv10.1 Kv10.2
HGNC, UniProt KCNV1, Q6PIU1 KCNV2, Q8TDN2 KCNS1, Q96KK3 KCNS2, Q9ULS6 KCNS3, Q9BQ31 KCNH1, O95259 KCNH5, Q8NCM2
Nomenclature Kv11.1 Kv11.2 Kv11.3 Kv12.1 Kv12.2 Kv12.3
HGNC, UniProt KCNH2, Q12809 KCNH6, Q9H252 KCNH7, Q9NS40 KCNH8, Q96L42 KCNH3, Q9ULD8 KCNH4, Q9UQ05
Associated subunits minK (KCNE1) and MiRP1 (KCNE2) minK (KCNE1) minK (KCNE1) minK (KCNE1) minK (KCNE1) and MiRP2
(KCNE3)
–
Channel blockers astemizole (pIC50 9) [486], terfenadine (pIC50 7.3)
[344], disopyramide (pIC50 4) [190]
– – – – –
Inhibitor E4031 (pIC50 8.1) [485] – – – – –
Selective channel blockers dofetilide (pKi 8.2) [372], ibutilide (pIC50 7.6–8)
[190, 326]
– – – – –
Functional Characteristics cardiac IKR – – – – –
Comments RPR260243 is an activator of Kv11.1 [185]. – – – – –
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Ryanodine receptors
Voltage-gated ion channels → Ryanodine receptors
Overview: The ryanodine receptors (RyRs) are found on in-
tracellular Ca2+ storage/release organelles. The family of RyR
genes encodes three highly related Ca2+ release channels:
RyR1, RyR2 and RyR3, which assemble as large tetrameric
structures. These RyR channels are ubiquitously expressed
in many types of cells and participate in a variety of im-
portant Ca2+ signaling phenomena (neurotransmission, se-
cretion, etc.). In addition to the three mammalian isoforms
described below, various nonmammalian isoforms of the
ryanodine receptor have been identiﬁed [392]. The func-
tion of the ryanodine receptor channels may also be
inﬂuenced by closely associated proteins such as the
tacrolimus (FK506)-binding protein, calmodulin [467], triadin,
calsequestrin, junctin and sorcin, and by protein kinases and
phosphatases.
Nomenclature RyR1 RyR2 RyR3
HGNC, UniProt RYR1, P21817 RYR2, Q92736 RYR3, Q15413
Endogenous activators cytosolic ATP (endogenous; mM range), cytosolic Ca2+ (endogenous; μM range),
luminal Ca2+ (endogenous)
cytosolic ATP (endogenous; mM range),
cytosolic Ca2+ (endogenous; μM range),
luminal Ca2+ (endogenous)
cytosolic ATP (endogenous; mM range),
cytosolic Ca2+ (endogenous; μM range)
Activators caffeine (pharmacological; mM range), ryanodine (pharmacological; nM - μM
range), suramin (pharmacological; μM range)
caffeine (pharmacological; mM range),
ryanodine (pharmacological; nM - μM
range), suramin (pharmacological; μM
range)
caffeine (pharmacological; mM range),
ryanodine (pharmacological; nM - μM
range)
Endogenous antagonists cytosolic Ca2+ Concentration range: >1×10−4M, cytosolic Mg2+ (mM range) cytosolic Ca2+ Concentration range:
>1×10−3M, cytosolic Mg2+ (mM range)
cytosolic Ca2+ Concentration range:
>1×10−3M, cytosolic Mg2+ (mM range)
Antagonists dantrolene – dantrolene
Channel blockers procaine, ruthenium red, ryanodine Concentration range: >1×10−4M procaine, ruthenium red, ryanodine
Concentration range: >1×10−4M
ruthenium red
Functional Characteristics Ca2+: (P Ca/P K 6˜) single-channel conductance: 90 pS (50mM Ca2+), 770 pS (200
mM K+)
Ca2+: (P Ca/P K6) single-channel
conductance: 90 pS (50mM Ca2+), 720 pS
(210 mM K+)
Ca2+: (P Ca/PK 6) single-channel
conductance: 140 pS (50mM Ca2+), 777 pS
(250 mM K+)
Comments RyR1 is also activated by depolarisation via DHP receptor, calmodulin at low
cytosolic Ca2+ concentrations, CaM kinase and PKA; antagonised by calmodulin at
high cytosolic Ca2+ concentrations
RyR2 is also activated by CaM kinase and
PKA; antagonised by calmodulin at high
cytosolic Ca2+ concentrations
RyR3 is also activated by calmodulin at low
cytosolic Ca2+ concentrations; antagonised
by calmodulin at high cytosolic Ca2+
concentrations
Comments: The modulators of channel function included in this table are those most commonly used to identify ryanodine-sensitive Ca2+ release pathways. Numerous other modulators of ryanodine
receptor/channel function can be found in the reviews listed below. The absence of a modulator of a particular isoform of receptor indicates that the action of that modulator has not been determined,
not that it is without effect. The potential role of cyclic ADP ribose as an endogenous regulator of ryanodine receptor channels is controversial. A region of RyR likely to be involved in ion translocation
and selection has been identiﬁed [112, 479].
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Further reading on Ryanodine receptors
O’Brien F et al. (2015) The ryanodine receptor provides high throughput Ca2+-release but is pre-
cisely regulated by networks of associated proteins: a focus on proteins relevant to phosphory-
lation. Biochem Soc Trans 43: 426-33 [PMID:26009186]
Samso M. (2017) A guide to the 3D structure of the ryanodine receptor type 1 by cryoEM. Protein
Sci 26: 52-68 [PMID:27671094]
Van Petegem F. (2015) Ryanodine receptors: allosteric ion channel giants. J Mol Biol 427: 31-53
[PMID:25134758]
Zalk R et al. (2017) Ca2+ Release Channels Join the ’Resolution Revolution’. Trends Biochem Sci 42:
543-555 [PMID:28499500]
Transient Receptor Potential channels
Voltage-gated ion channels → Transient Receptor Potential channels
Overview:
The TRP superfamily of channels (nomenclature as agreed by
NC-IUPHAR [70, 455]), whose foundermember is theDrosophila
Trp channel, exists in mammals as six families; TRPC, TRPM,
TRPV, TRPA, TRPP and TRPML based on amino acid homologies.
TRP subunits contain six putative transmembrane domains and
assemble as homo- or hetero-tetramers to form cation selective
channels with diverse modes of activation and varied permeation
properties (reviewed by [307]). Established, or potential, physio-
logical functions of the individual members of the TRP families are
discussed in detail in the recommended reviews and a compilation
edited by Islam [168]. The established, or potential, involvement
of TRP channels in disease is reviewed in [196, 288] and [290], to-
gether with a special edition of Biochemica et Biophysica Acta on the
subject [288]. The pharmacology of most TRP channels is poorly
developed [455]. Broad spectrum agents are listed in the tables
along with more selective, or recently recognised, ligands that are
ﬂagged by the inclusion of a primary reference. Most TRP chan-
nels are regulated by phosphoinostides such as PtIns(4,5)P2 and
IP3 although the effects reported are often complex, occasion-
ally contradictory, and likely to be dependent upon experimen-
tal conditions, such as intracellular ATP levels (reviewed by [291,
353, 424]). Such regulation is generally not included in the ta-
bles.When thermosensitivity is mentioned, it refers speciﬁcally
to a high Q10 of gating, often in the range of 10-30, but does
not necessarily imply that the channel’s function is to act as a
’hot’ or ’cold’ sensor. In general, the search for TRP activators has
led to many claims for temperature sensing, mechanosensation,
and lipid sensing. All proteins are of course sensitive to energies
of binding, mechanical force, and temperature, but the issue is
whether the proposed input is within a physiologically relevant
range resulting in a response.
TRPA (ankyrin) family
TRPA1 is the sole mammalian member of this group (reviewed by
[114]). TRPA1 activation of sensory neurons contribute to no-
ciception [177, 266, 386]. Pungent chemicals such as mustard
oil (AITC), allicin, and cinnamaldehyde activate TRPA1 by mod-
iﬁcation of free thiol groups of cysteine side chains, especially
those located in its amino terminus [22, 149, 251, 253]. Alkenals
with α, β-unsaturated bonds, such as propenal (acrolein), bute-
nal (crotylaldehyde), and 2-pentenal can react with free thiols
via Michael addition and can activate TRPA1. However, potency
appears to weaken as carbon chain length increases [11, 22]. Cova-
lent modiﬁcation leads to sustained activation of TRPA1. Chemi-
cals including carvacrol, menthol, and local anesthetics reversibly
activate TRPA1 by non-covalent binding [186, 222, 460, 461].
TRPA1 is not mechanosensitive under physiological conditions,
but can be activated by cold temperatures [86, 187]. The electron
cryo-EM structure of TRPA1 [315] indicates that it is a 6-TM ho-
motetramer. Each subunit of the channel contains two short ‘pore
helices’ pointing into the ion selectivity ﬁlter, which is big enough
to allow permeation of partially hydrated Ca2+ ions. A coiled-
coil domain in the carboxy-terminal region forms the cytoplas-
mic stalk of the channel, and is surrounded by 16 ankyrin repeat
domains, which are speculated to interdigitate with an overlying
helix-turn-helix and putative β-sheet domain containing cysteine
residues targeted by electrophilic TRPA1 agonists. The TRP do-
main, a helix at the base of S6, runs perpendicular to the pore
helices suspended above the ankyrin repeats below, where it may
contribute to regulation of the lower pore. The coiled-coil stalk
mediates bundling of the four subunits through interactions be-
tween predicted α-helices at the base of the channel.
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Nomenclature TRPA1
HGNC, UniProt TRPA1, O75762
Chemical activators Isothiocyanates (covalent) and 1,4-dihydropyridines (non-covalent)
Physical activators Cooling (<17°C) (disputed)
Activators acrolein (covalent) (pEC50 5.3) [physiological voltage] [22], allicin (covalent) (pEC50 5.1) [physiological voltage] [23], 9-tetrahydrocannabinol (non-covalent) (pEC50 4.9)
[-60mV] [177], nicotine (non-covalent) (pEC50 4.8) [-75mV] [400], thymol (non-covalent) (pEC50 4.7) Concentration range: 6.2×10−6M-2.5×10−5M [220], URB597
(non-covalent) (pEC50 4.6) [287], (-)-menthol (Menthol is also active at the mouse TRPA1, but becomes inhibitory at >100μM) (pEC50 4–4.5) [186, 458], cinnamaldehyde
(covalent) (pEC50 4.2) [physiological voltage] [14] – Mouse, icilin (non-covalent) Concentration range: 1×10−4M [physiological voltage] [386] – Mouse
Selective activators chlorobenzylidene malononitrile (covalent) (pEC50 6.7) [41], formalin (covalent. This level of activity is also observed for rat TRPA1) (pEC50 3.4) [253, 266] – Mouse
Channel blockers AP18 (pIC50 5.5) [328], ruthenium red (pIC50 5.5) [-80mV] [280] – Mouse, HC030031 (pIC50 5.2) [266]
Functional Characteristics γ = 87–100 pS; conducts mono- and di-valent cations non-selectively (PCa/PNa = 0.84); outward rectiﬁcation; activated by elevated intracellular Ca2+
TRPC (canonical) family
Members of the TRPC subfamily (reviewed by [2, 8, 27, 31, 111,
194, 312, 337]) fall into the subgroups outlined below. TRPC2 is
a pseudogene in humans. It is generally accepted that all TRPC
channels are activated downstream of Gq/11-coupled receptors, or
receptor tyrosine kinases (reviewed by [333, 415, 455]). A compre-
hensive listing of G-protein coupled receptors that activate TRPC
channels is given in [2]. Hetero-oligomeric complexes of TRPC
channels and their association with proteins to form signalling
complexes are detailed in [8] and [195]. TRPC channels have fre-
quently been proposed to act as store-operated channels (SOCs)
(or compenents of mulimeric complexes that form SOCs), acti-
vated by depletion of intracellular calcium stores (reviewed by [8,
61, 321, 334, 359, 475]). However, the weight of the evidence
is that they are not directly gated by conventional store-operated
mechanisms, as established for Stim-gated Orai channels. TRPC
channels are not mechanically gated in physiologically relevant
ranges of force. All members of the TRPC family are blocked by
2-APB and SKF96365 [139, 140]. Activation of TRPC channels by
lipids is discussed by [27].
TRPC1/C4/C5 subgroup
TRPC4/C5may be distinguished from other TRP channels by their
potentiation by micromolar concentrations of La3+. TRPC2 is a
pseudogene in humans, but in other mammals appears to be an
ion channel localized to microvilli of the vomeronasal organ. It
is required for normal sexual behavior in response to pheromones
in mice. It may also function in the main olfactory epithelia in
mice [236, 304, 305, 472, 473, 474, 487].
TRPC3/C6/C7 subgroup
All members are activated by diacylglycerol independent of pro-
tein kinase C stimulation [140].
Nomenclature TRPC1 TRPC2 TRPC3 TRPC4
HGNC, UniProt TRPC1, P48995 TRPC2, – TRPC3, Q13507 TRPC4, Q9UBN4
Chemical activators NO-mediated cysteine S-nitrosylation Diacylglycerol (SAG, OAG, DOG): strongly
inhibited by Ca2+/CaM once activated by
DAG [380]
diacylglycerols NO-mediated cysteine S-nitrosylation,
potentiation by extracellular protons
Physical activators membrane stretch – – –
Endogenous activators – Intracellular Ca2+ – –
Activators – DOG Concentration range: 1×10−4M
[-80mV] [248] – Mouse, SAG Concentration
range: 1×10−4M [-80mV] [248] – Mouse
– La3+ (μM range)
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Nomenclature TRPC1 TRPC2 TRPC3 TRPC4
Channel blockers 2-APB [-70mV] [389], Gd3+ Concentration
range: 2×10−5M [-70mV] [487], La3+
Concentration range: 1×10−4M [-70mV] [389]
2-APB Concentration range: 5×10−5M
[-70mV – 80mV] [248] – Mouse, U73122
(may be indirect) Concentration range:
1×10−5M – Mouse
Gd3+ (pEC50 7) [-60mV] [137],
BTP2 (pIC50 6.5) [-80mV] [141],
Pyr3 (pIC50 6.2) [197], La3+
(pIC50 5.4) [-60mV] [137], 2-APB
(pIC50 5) [physiological voltage]
[234], Ni2+, SKF96365
ML204 (pIC50 5.5) [269], La3+ (mM
range), SKF96365, niﬂumic acid
Concentration range: 3×10−5M [-60mV]
[432] – Mouse
Functional Characteristics It is not yet clear that TRPC1 forms a
homomer. It does form heteromers with
TRPC4 and TRPC5
γ = 42 pS linear single channel conductance
in 150 mM symmetrical Na+ in vomeronasal
sensory neurons. PCa/PNa = 2.7; permeant to
Na+, Cs+, Ca2+, but not NMDG [305, 473]
γ = 66 pS; conducts mono and
di-valent cations non-selectively
(PCa/PNa = 1.6); monovalent
cation current suppressed by
extracellular Ca2+; dual (inward
and outward) rectiﬁcation
γ = 30 –41 pS, conducts mono and
di-valent cations non-selectively (PCa/PNa
= 1.1 – 7.7); dual (inward and outward)
rectiﬁcation
Nomenclature TRPC5 TRPC6 TRPC7
HGNC, UniProt TRPC5, Q9UL62 TRPC6, Q9Y210 TRPC7, Q9HCX4
Chemical activators NO-mediated cysteine S-nitrosylation (disputed), potentiation
by extracellular protons
Diacylglycerols diacylglycerols
Physical activators Membrane stretch Membrane stretch –
Endogenous activators intracellular Ca2+ (at negative potentials) (pEC50 6.2),
lysophosphatidylcholine
20-HETE, arachidonic acid, lysophosphatidylcholine –
Activators Gd3+ Concentration range: 1×10−4M, La3+ (μM range), Pb2+
Concentration range: 5×10−6M, genistein (independent of
tyrosine kinase inhibition) [452]
ﬂufenamate, hyp 9 [226], hyperforin [227] –
Channel blockers KB-R7943 (pIC50 5.9) [207], ML204 (pIC50 ∼5) [269], 2-APB
(pIC50 4.7) [-80mV] [464], La3+ Concentration range: 5×10−3M
[-60mV] [178] – Mouse
Gd3+ (pIC50 5.7) [-60mV] [164] – Mouse, SKF96365 (pIC50
5.4) [-60mV] [164] – Mouse, La3+ (pIC50 ∼5.2), amiloride
(pIC50 3.9) [-60mV] [164] – Mouse, Cd2+ (pIC50 3.6)
[-60mV] [164] – Mouse, 2-APB, ACAA, GsMTx-4,
Extracellular H+, KB-R7943, ML9
2-APB, La3+ Concentration range: 1×10−4M
[-60mV] [303] – Mouse, SKF96365
Concentration range: 2.5×10−5M [-60mV]
[303] – Mouse, amiloride
Functional Characteristics γ = 41-63 pS; conducts mono-and di-valent cations
non-selectively (PCa/PNa = 1.8 – 9.5); dual rectiﬁcation (inward
and outward) as a homomer, outwardly rectifying when
expressed with TRPC1 or TRPC4
γ = 28-37 pS; conducts mono and divalent cations with a
preference for divalents (PCa/PNa = 4.5–5.0); monovalent
cation current suppressed by extracellular Ca2+ and Mg2+,
dual rectiﬁcation (inward and outward), or inward
rectiﬁcation
γ = 25–75 pS; conducts mono and divalent
cations with a preference for divalents (PCa/
PCs = 5.9); modest outward rectiﬁcation
(monovalent cation current recorded in the
absence of extracellular divalents); monovalent
cation current suppressed by extracellular
Ca2+ and Mg2+
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TRPM (melastatin) family
Members of the TRPM subfamily (reviewed by [109, 139, 321,
482]) fall into the ﬁve subgroups outlined below.
TRPM1/M3 subgroup
In darkness, glutamate released by the photoreceptors and ON-
bipolar cells binds to the metabotropic glutamate receptor 6 ,
leading to activation of Go . This results in the closure of
TRPM1. When the photoreceptors are stimulated by light, glu-
tamate release is reduced, and TRPM1 channels are more ac-
tive, resulting in cell membrane depolarization. Human TRPM1
mutations are associated with congenital stationary night blind-
ness (CSNB), whose patients lack rod function. TRPM1 is also
found melanocytes. Isoforms of TRPM1 may present in
melanocytes, melanoma, brain, and retina. In melanoma cells,
TRPM1 is prevalent in highly dynamic intracellular vesicular
structures [165, 298].TRPM3 (reviewed by [301]) exists as mul-
tiple splice variants four of which (mTRPM3α1, mTRPM3α2,
hTRPM3a and hTRPM31325) have been characterised and found
to differ signiﬁcantly in their biophysical properties. TRPM3
is expressed in somatosensory neurons and may be important in
development of heat hyperalgesia during inﬂammation. TRPM3 is
frequently coexpressed with TRPA1 and TRPV1 in these neurons.
TRPM3 is expressed in pancreatic beta cells as well as brain, pi-
tuitary gland, eye, kidney, and adipose tissue [300, 408]. TRPM3
may contribute to the detection of noxious heat [428].
TRPM2
TRPM2 is activated under conditions of oxidative stress (respira-
tory burst of phagocytic cells) and ischemic conditions. How-
ever, the direct activators are ADPR(P) and calcium. As for many
ion channels, PIP2 must also be present (reviewed by [468]). Nu-
merous splice variants of TRPM2 exist which differ in their ac-
tivation mechanisms [96]. The C-terminal domain contains a
TRP motif, a coiled-coil region, and an enzymatic NUDT9 ho-
mologous domain. TRPM2 appears not to be activated by
NAD, NAAD, or NAADP, but is directly activated by ADPRP
(adenosine-5’-O-disphosphoribose phosphate) [417].
TRPM4/5 subgroup
TRPM4 and TRPM5 have the distinction within all TRP channels
of being impermeable to Ca2+ [455]. A splice variant of TRPM4
(i.e.TRPM4b) and TRPM5 are molecular candidates for endoge-
nous calcium-activated cation (CAN) channels [130]. TRPM4 is
active in the late phase of repolarization of the cardiac ventricu-
lar action potential. TRPM4 enhances beta adrenergic-mediated
inotropy. Mutations are associated with conduction defects [170,
263, 381]. TRPM4 has been shown to be an important regulator
of Ca2+ entry in to mast cells [420] and dendritic cell migration
[17]. TRPM5 in taste receptor cells of the tongue appears essen-
tial for the transduction of sweet, amino acid and bitter stimuli
[235] TRPM5 contributes to the slow afterdepolarization of layer
5 neurons in mouse prefrontal cortex [223].
TRPM6/7 subgroup
TRPM6 and 7 combine channel and enzymatic activities
(‘chanzymes’). These channels have the unusual property of per-
meation by divalent (Ca2+, Mg2+, Zn2+) and monovalent cations,
high single channel conductances, but overall extremely small
inward conductance when expressed to the plasma membrane.
They are inhibited by internal Mg2+ at ˜0.6 mM, around the free
level of Mg2+ in cells. Whether they contribute to Mg2+ home-
ostasis is a contentious issue. When either gene is deleted in mice,
the result is embryonic lethality. The C-terminal kinase region is
cleaved under unknown stimuli, and the kinase phosphorylates
nuclear histones.
TRPM8
Is a channel activated by cooling and pharmacological agents
evoking a ‘cool’ sensation and participates in the thermosensa-
tion of cold temperatures [24, 71, 90] reviewed by [200, 244, 277,
425].
Nomenclature TRPM1 TRPM2 TRPM3
HGNC, UniProt TRPM1, Q7Z4N2 TRPM2, O94759 TRPM3, Q9HCF6
Physical activators – Heat ˜35°C heat (Q10 = 7.2 between 15 - 25°C; Vriens et al., 2011), hypotonic
cell swelling [428]
Endogenous activators pregnenolone sulphate [216] intracellular cADPR (pEC50 5) [-80mV – -60mV] [26, 204, 410],
intracellular ADP ribose (pEC50 3.9–4.4) [-80mV] [325],
intracellular Ca2+ (perhaps via calmodulin), H2O2 Concentration
range: 5×10−7M-5×10−5M [physiological voltage] [110, 138,
209, 376, 443], membrane PIP2 [416], arachidonic acid
Concentration range: 1×10−5M-3×10−5M [physiological voltage]
[138]
sphingosine (pEC50 4.9) [physiological voltage] [127],
epipregnanolone sulphate [259], pregnenolone sulphate [429],
sphinganine Concentration range: 2×10−5M [physiological voltage]
[127]
Activators – GEA 3162 nifedipine
Gating inhibitors – 2-APB Concentration range: 1×10−4M [physiological voltage] [464]
Endogenous channel blockers Zn2+ (pIC50 6) Zn2+ (pIC50 6), extracellular H+ Mg2+ Concentration range: 9×10−3M [-80mV – 80mV] [299] –
Mouse, extracellular Na+ (TRPM3α2 only)
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Nomenclature TRPM1 TRPM2 TRPM3
Channel blockers – 2-APB (pIC50 6.1) [-60mV] [411], ACAA (pIC50 5.8)
[physiological voltage] [208], clotrimazole Concentration range:
3×10−6M-3×10−5M [-60mV – -15mV] [147], econazole
Concentration range: 3×10−6M-3×10−5M [-60mV – -15mV]
[147], ﬂufenamic acid Concentration range: 5×10−5M-1×10−3M
[-60mV – -50mV] [146, 411], miconazole Concentration range:
1×10−5M [-60mV] [411]
Gd3+ Concentration range: 1×10−4M [-80mV – 80mV] [126, 219],
La3+ Concentration range: 1×10−4M [physiological voltage] [126,
219]
Functional Characteristics Conducts mono- and di-valent
cations non-selectively, dual
rectiﬁcation (inward and outward)
γ = 52-60 pS at negative potentials, 76 pS at positive potentials;
conducts mono- and di-valent cations non-selectively (PCa/PNa =
0.6-0.7); non-rectifying; inactivation at negative potentials;
activated by oxidative stress probably via PARP-1, PARP inhibitors
reduce activation by oxidative stress, activation inhibited by
suppression of APDR formation by glycohydrolase inhibitors.
TRPM31235: γ = 83 pS (Na+ current), 65 pS (Ca2+ current);
conducts mono and di-valent cations non-selectively (PCa/PNa =
1.6) TRPM3α1: selective for monovalent cations (PCa/PCs ˜0.1);
TRPM3α2: conducts mono- and di-valent cations non-selectively
(PCa/PCs = 1–10);
Outwardly rectifying (magnitude varies between spice variants)
Nomenclature TRPM4 TRPM5 TRPM6
HGNC, UniProt TRPM4, Q8TD43 TRPM5, Q9NZQ8 TRPM6, Q9BX84
EC number – – 2.7.11.1
Other channel blockers Intracellular nucleotides including ATP, ADP,
adenosine 5’-monophosphate and
AMP-PNP with an IC50 range of 1.3-1.9 μM
– –
Other chemical activators – – constitutively active, activated by reduction of intracellular Mg2+
Physical activators Membrane depolarization (V½ = -20 mV to +
60 mV dependent upon conditions) in the
presence of elevated [Ca2+]i, heat (Q10 =
8.5 @ +25 mV between 15 and 25°C)
membrane depolarization (V½ = 0 to +
120 mV dependent upon conditions),
heat (Q10 = 10.3 @ -75 mV between
15 and 25°C)
–
Endogenous activators intracellular Ca2+ (pEC50 3.9–6.3) [-100mV
– 100mV] [289, 293, 294, 398]
intracellular Ca2+ (pEC50 4.5–6.2)
[-80mV – 80mV] [155, 241, 418] –
Mouse
extracellular H+ (μM range), intracellular Mg2+
Activators BTP2 (pEC50 8.1) [-80mV] [398],
decavanadate (pEC50 5.7) [-100mV] [293]
– 2-APB (Potentiation) (pEC50 3.4–3.7) [-120mV – 100mV] [230]
Gating inhibitors ﬂufenamic acid (pIC50 5.6) [100mV] [418] –
Mouse, clotrimazole Concentration range:
1×10−6M-1×10−5M [100mV] [297]
– –
Endogenous channel blockers – – Mg2+ (inward current mediated by monovalent cations is blocked) (pIC50 5.5–6),
Ca2+ (inward current mediated by monovalent cations is blocked) (pIC50 5.3–5.3)
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Nomenclature TRPM4 TRPM5 TRPM6
Channel blockers 9-phenanthrol (pIC50 4.6–4.8) [122],
spermine (pIC50 4.2) [100mV] [295],
adenosine (pIC50 3.2)
ﬂufenamic acid (pIC50 4.6),
intracellular spermine (pIC50 4.4),
Extracellular H+ (pIC50 3.2)
ruthenium red (pIC50 7) [voltage dependent -120mV]
Functional Characteristics γ = 23 pS (within the range 60 to +60 mV);
permeable to monovalent cations;
impermeable to Ca2+; strong outward
rectiﬁcation; slow activation at positive
potentials, rapid deactivation at negative
potentials, deactivation blocked by
decavanadate
γ = 15-25 pS; conducts monovalent
cations selectively (PCa/PNa = 0.05);
strong outward rectiﬁcation; slow
activation at positive potentials, rapid
inactivation at negative potentials;
activated and subsequently
desensitized by [Ca2+]I
γ= 40–87 pS; permeable to mono- and di-valent cations with a preference for
divalents (Mg2+ > Ca2+; PCa/PNa = 6.9), conductance sequence Zn2+ > Ba2+ >
Mg2+= Ca2+ = Mn2+ > Sr2+ > Cd2+> Ni2+; strong outward rectiﬁcation
abolished by removal of extracellular divalents, inhibited by intracellular Mg2+
(IC50 = 0.5 mM) and ATP
Comments – TRPM5 is not blocked by ATP –
Nomenclature TRPM7 TRPM8
HGNC, UniProt TRPM7, Q96QT4 TRPM8, Q7Z2W7
EC number 2.7.11.1 –
Physical activators – depolarization (V½ ˜+50 mV at 15°C), cooling (< 22-26°C)
Endogenous activators intracellular ATP, Extracellular H+, cyclic AMP (elevated cAMP levels) –
Activators 2-APB Concentration range: >1×10−3M [279] – Mouse icilin (pEC50 6.7–6.9) [physiological voltage] [9, 28] – Mouse,
(-)-menthol (inhibited by intracellular Ca2+) (pEC50 4.6) [-120mV –
160mV] [423]
Selective activators – WS-12 (pEC50 4.9) [physiological voltage] [249, 369] – Rat
Channel blockers spermine (Reversible, voltage dependent inhibition in RBL2H3 rats) (pKi 5.6) [-110mV – 80mV] [206] –
Rat, 2-APB (Reversible inhibition) (pIC50 3.8) [-100mV – 100mV] [230] – Mouse, carvacrol (Reversible
inhibition) (pIC50 3.5) [-100mV – 100mV] [310] – Mouse, Mg2+ (Reversible inhibition) (pIC50 2.5)
[80mV] [279] – Mouse, La3+ Concentration range: 2×10−3M [-100mV – 100mV] [356] – Mouse
BCTC (pIC50 6.1) [physiological voltage] [28] – Mouse, 2-APB (pIC50
4.9–5.1) [100mV – -100mV] [157, 284] – Mouse, capsazepine (pIC50
4.7) [physiological voltage] [28] – Mouse
Functional Characteristics γ = 40-105 pS at negative and positive potentials respectively; conducts mono-and di-valent cations
with a preference for monovalents (PCa/PNa = 0.34); conductance sequence Ni2+ > Zn2+ > Ba2+ =
Mg2+ > Ca2+ = Mn2+ > Sr2+ > Cd2+; outward rectiﬁcation, decreased by removal of extracellular
divalent cations; inhibited by intracellular Mg2+, Ba2+, Sr2+, Zn2+, Mn2+ and Mg.ATP (disputed);
activated by and intracellular alkalinization; sensitive to osmotic gradients
γ = 40-83 pS at positive potentials; conducts mono- and di-valent
cations non-selectively (PCa/PNa = 1.0–3.3); pronounced outward
rectiﬁcation; demonstrates densensitization to chemical agonists and
adaptation to a cold stimulus in the presence of Ca2+; modulated by
lysophospholipids and PUFAs
Comments 2-APB acts as a channel blocker in the μM range. cannabidiol and 9-tetrahydrocannabinol are examples of
cannabinoid activators. TRPM8 is insensitive to ruthenium red. icilin
requires intracellular Ca2+ for full agonist activity.
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TRPML (mucolipin) family
The TRPML family [75, 336, 339, 463, 476] consists of three
mammalian members (TRPML1-3). TRPML channels are proba-
bly restricted to intracellular vesicles and mutations in the gene
(MCOLN1) encoding TRPML1 (mucolipin-1) are one cause of the
neurodegenerative disorder mucolipidosis type IV (MLIV) in man.
TRPML1 is a cation selective ion channel that is important for sort-
ing/transport of endosomes in the late endocytotic pathway and
speciﬁcally fusion between late endosome-lysosome hybrid vesi-
cles. TRPML2 and TRPML3 show increased channel activity in low
extracellular sodium and are activated by similar small molecules
[125]. TRPML3 is important for hair cell maturation, stereocilia
maturation and intracellular vesicle transport. A naturally occur-
ring gain of function mutation in TRPML3 (i.e. A419P) results
in the varitint waddler (Va) mouse phenotype (reviewed by [292,
339]).
Nomenclature TRPML1 TRPML2 TRPML3
HGNC, UniProt MCOLN1, Q9GZU1 MCOLN2, Q8IZK6 MCOLN3, Q8TDD5
Activators TRPML1Va: Constitutively active, current potentiated by
extracellular acidiﬁcation (equivalent to intralysosomal
acidiﬁcation)
TRPML2Va: Constitutively active, current
potentiated by extracellular acidiﬁcation
(equivalent to intralysosomal acidiﬁcation)
TRPML3Va: Constitutively active, current inhibited by
extracellular acidiﬁcation (equivalent to intralysosomal
acidiciﬁcation)
Wild type TRPML3: Activated by Na+-free extracellular
(extracytosolic) solution and membrane
depolarization, current inhibited by extracellular
acidiﬁcation (equivalent to intralysosomal
acidiciﬁcation)
Channel blockers Gd3+ (pIC50 4.7) [-80mV] [281] – Mouse
Functional Characteristics TRPML1Va: γ = 40 pS and 76-86 pS at very negative holding
potentials with Fe2+ and monovalent cations as charge carriers,
respectively; conducts Na+∼= K+>Cs+ and divalent cations
(Ba2+>Mn2+>Fe2+>Ca2+> Mg2+> Ni2+>Co2+>
Cd2+>Zn2+Cu2+) protons; monovalent cation ﬂux suppressed
by divalent cations (e.g. Ca2+, Fe2+); inwardly rectifying
TRPML1Va: Conducts Na+; monovalent cation
ﬂux suppressed by divalent cations; inwardly
rectifying
TRPML3Va: γ = 49 pS at very negative holding
potentials with monovalent cations as charge carrier;
conducts Na+ > K+ > Cs+ with maintained current in
the presence of Na+, conducts Ca2+ and Mg2+, but
not Fe2+, impermeable to protons; inwardly rectifying
Wild type TRPML3: γ = 59 pS at negative holding
potentials with monovalent cations as charge carrier;
conducts Na+ > K+ > Cs+ and Ca2+ (PCa/PK ∼= 350),
slowly inactivates in the continued presence of Na+
within the extracellular (extracytosolic) solution;
outwardly rectifying
TRPP (polycystin) family
The TRPP family (reviewed by [87, 89, 118, 153, 451]) or PKD2 family is comprised of PKD2, PKD2L1 and PKD2L2, which have been renamed TRPP1, TRPP2 and TRPP3, respectively [455]. They are clearly
distinct from the PKD1 family, whose function is unknown. Although still being sorted out, TRPP family members appear to be 6TM spanning nonselective cation channels.
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Nomenclature TRPP1 TRPP2 TRPP3
HGNC, UniProt PKD2, Q13563 PKD2L1, Q9P0L9 PKD2L2, Q9NZM6
Activators – Calmidazolium (in primary cilia): 10 μM –
Channel blockers – phenamil (pIC50 6.9), benzamil (pIC50 6), ethylisopropylamiloride (pIC50 5), amiloride
(pIC50 3.8), Gd3+ Concentration range: 1×10−4M [-50mV] [59], La3+ Concentration range:
1×10−4M [-50mV] [59], ﬂufenamate
–
Functional Characteristics The channel properties of TRPP1 (PKD2) have not
been determined
Currents have been measured directly from primary cilia and also when expressed on plasma
membranes. Primary cilia appear to contain heteromeric TRPP2 + PKD1-L1, underlying a
gently outwardly rectifying nonselective conductance (PCa/PNa ˜6: PKD1-L1 is a 12 TM
protein of unknown topology). Primary cilia heteromeric channels have an inward single
channel conductance of 80 pS and an outward single channel conductance of 95 pS.
Presumed homomeric TRPP2 channels are gently outwardly rectifying. Single channel
conductance is 120 pS inward, 200 pS outward [82].
–
TRPV (vanilloid) family
Members of the TRPV family (reviewed by [421]) can broadly be
divided into the non-selective cation channels, TRPV1-4 and the
more calcium selective channels TRPV5 and TRPV6.
TRPV1-V4 subfamily
TRPV1 is involved in the development of thermal hyperalgesia
following inﬂammation and may contribute to the detection of
noxius heat (reviewed by [330, 382, 395]). Numerous splice vari-
ants of TRPV1 have been described, some of which modulate the
activity of TRPV1, or act in a dominant negative manner when co-
expressed with TRPV1 [366]. The pharmacology of TRPV1 chan-
nels is discussed in detail in [132] and [427]. TRPV2 is probably not
a thermosensor in man [309], but has recently been implicated in
innate immunity [238]. TRPV3 and TRPV4 are both thermosen-
sitive. There are claims that TRPV4 is also mechanosensitive, but
this has not been established to be within a physiological range in
a native environment [47, 232].
TRPV5/V6 subfamily
Under physiological conditions, TRPV5 and TRPV6 are calcium
selective channels involved in the absorption and reabsorption of
calcium across intestinal and kidney tubule epithelia (reviewed by
[81, 104, 278, 449]).
Nomenclature TRPV1 TRPV2
HGNC, UniProt TRPV1, Q8NER1 TRPV2, Q9Y5S1
Other chemical activators NO-mediated cysteine S-nitrosylation –
Physical activators depolarization (V½ ˜0 mV at 35°C), noxious heat (> 43°C at pH 7.4) noxious heat (> 35°C; rodent, not human) [285]
Endogenous activators extracellular H+ (at 37°C) (pEC50 5.4), 12S-HPETE (pEC50 5.1) [-60mV] [161] – Rat, 15S-HPETE
(pEC50 5.1) [-60mV] [161] – Rat, LTB4 (pEC50 4.9) [-60mV] [161] – Rat, 5S-HETE
–
Activators resiniferatoxin (pEC50 8.4) [physiological voltage] [374], capsaicin (pEC50 7.5) [-100mV –
160mV] [423], camphor, diphenylboronic anhydride, phenylacetylrinvanil [12]
2-APB (pEC50 5) [285, 340] – Rat, 9-tetrahydrocannabinol (pEC50 4.8)
[340] – Rat, cannabidiol (pEC50 4.5) [340], probenecid (pEC50 4.5) [15] –
Rat, 2-APB (pEC50 3.8–3.9) [physiological voltage] [157, 179] – Mouse,
diphenylboronic anhydride Concentration range: 1×10−4M [-80mV] [66,
179] – Mouse
Selective activators olvanil (pEC50 7.7) [physiological voltage] [374], DkTx (pEC50 6.6) [physiological voltage] [36] –
Rat
–
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(continued)
Nomenclature TRPV1 TRPV2
Channel blockers 5’-iodoresiniferatoxin (pIC50 8.4), 6-iodo-nordihydrocapsaicin (pIC50 8), BCTC (pIC50 7.5) [57],
capsazepine (pIC50 7.4) [-60mV] [265], ruthenium red (pIC50 6.7–7)
ruthenium red (pIC50 6.2), TRIM Concentration range: 5×10−4M [179] –
Mouse
Selective channel blockers AMG517 (pIC50 9) [35], AMG628 (pIC50 8.4) [435] – Rat, A425619 (pIC50 8.3) [100], A778317
(pIC50 8.3) [30], SB366791 (pIC50 8.2) [134], JYL1421 (pIC50 8) [440] – Rat, JNJ17203212
(pIC50 7.8) [physiological voltage] [393], SB452533 (pKB 7.7), SB705498 (pIC50 7.1) [133]
–
Labelled ligands [3H]A778317 (Channel blocker) (pKd 8.5) [30], [
125I]resiniferatoxin (Channel blocker) (pIC50
8.4) [-50mV] [430] – Rat, [3H]resiniferatoxin (Activator)
–
Functional Characteristics γ = 35 pS at – 60 mV; 77 pS at + 60 mV, conducts mono and di-valent cations with a selectivity
for divalents (PCa/PNa = 9.6); voltage- and time- dependent outward rectiﬁcation; potentiated
by ethanol; activated/potentiated/upregulated by PKC stimulation; extracellular acidiﬁcation
facilitates activation by PKC; desensitisation inhibited by PKA; inhibited by Ca2+/ calmodulin;
cooling reduces vanilloid-evoked currents; may be tonically active at body temperature
Conducts mono- and di-valent cations (PCa/PNa = 0.9–2.9); dual (inward and
outward) rectiﬁcation; current increases upon repetitive activation by heat;
translocates to cell surface in response to IGF-1 to induce a constitutively
active conductance, translocates to the cell surface in response to membrane
stretch
Nomenclature TRPV3 TRPV4
HGNC, UniProt TRPV3, Q8NET8 TRPV4, Q9HBA0
Other chemical activators NO-mediated cysteine S-nitrosylation Epoxyeicosatrieonic acids and NO-mediated cysteine S-nitrosylation
Physical activators depolarization (V½ ˜+80 mV, reduced to more negative values following heat stimuli), heat
(23°C - 39°C, temperature threshold reduces with repeated heat challenge)
Constitutively active, heat (> 24°C - 32°C), mechanical stimuli
Activators incensole acetate (pEC50 4.8) [273] – Mouse, 2-APB (pEC50 4.6) [-80mV – 80mV] [67] –
Mouse, diphenylboronic anhydride (pEC50 4.1–4.2) [voltage dependent -80mV – 80mV] [66]
– Mouse, (-)-menthol (pEC50 1.7) [-80mV – 80mV] [252] – Mouse, camphor Concentration
range: 1×10−3M-2×10−3M [-60mV] [271] – Mouse, carvacrol Concentration range:
5×10−4M [-80mV – 80mV] [461] – Mouse, eugenol Concentration range: 3×10−3M [-80mV
– 80mV] [461] – Mouse, thymol Concentration range: 5×10−4M [-80mV – 80mV] [461] –
Mouse
phorbol 12-myristate 13-acetate (pEC50 7.9) [physiological voltage] [459]
Selective activators 6-tert-butyl-m-cresol (pEC50 3.4) [426] – Mouse GSK1016790A (pEC50 8.7) [physiological voltage] [409], 4α-PDH (pEC50 7.1)
[physiological voltage] [198] – Mouse, RN1747 (pEC50 6.1) [physiological
voltage] [422], bisandrographolide (pEC50 6) [-60mV] [377] – Mouse, 4α-PDD
Concentration range: 3×10−7M [physiological voltage] [459]
Channel blockers diphenyltetrahydrofuran (pIC50 5–5.2) [-80mV – 80mV] [66] – Mouse, ruthenium red
Concentration range: 1×10−6M [-60mV] [322] – Mouse
Gd3+, La3+, ruthenium red Concentration range: 1×10−6M [physiological
voltage] [172], ruthenium red Concentration range: 2×10−7M [physiological
voltage] [131] – Rat
Selective channel blockers – HC067047 (pIC50 7.3) [-40mV] [102], RN1734 (pIC50 5.6) [physiological
voltage] [422]
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Nomenclature TRPV3 TRPV4
Functional Characteristics γ = 197 pS at = +40 to +80 mV, 48 pS at negative potentials; conducts mono- and di-valent
cations; outward rectiﬁcation; potentiated by arachidonic acid
γ = ˜60 pS at –60 mV, ˜90-100 pS at +60 mV; conducts mono- and di-valent
cations with a preference for divalents (PCa/PNa =6–10); dual (inward and
outward) rectiﬁcation; potentiated by intracellular Ca2+ via Ca2+/ calmodulin;
inhibited by elevated intracellular Ca2+via an unknown mechanism (IC50 = 0.4
μM)
Nomenclature TRPV5 TRPV6
HGNC, UniProt TRPV5, Q9NQA5 TRPV6, Q9H1D0
Other channel blockers Pb2+ = Cu2+ = Gd3+ > Cd2+ > Zn2+ > La3+ > Co2+ > Fe2 –
Activators constitutively active (with strong buffering of intracellular Ca2+) 2-APB
constitutively active (with strong buffering of intracellular Ca2+)
Channel blockers ruthenium red (pIC50 6.9), Mg2+ ruthenium red (pIC50 5) [-80mV] [152] – Mouse, Cd2+, La3+, Mg2+
Functional Characteristics γ = 59–78 pS for monovalent ions at negative potentials, conducts mono- and di-valents
with high selectivity for divalents (PCa/PNa > 107); voltage- and time- dependent inward
rectiﬁcation; inhibited by intracellular Ca2+ promoting fast inactivation and slow
downregulation; feedback inhibition by Ca2+ reduced by calcium binding protein
80-K-H; inhibited by extracellular and intracellular acidosis; upregulated by
1,25-dihydrovitamin D3
γ = 58–79 pS for monovalent ions at negative potentials, conducts mono- and
di-valents with high selectivity for divalents (PCa/PNa > 130); voltage- and
time-dependent inward rectiﬁcation; inhibited by intracellular Ca2+ promoting fast
and slow inactivation; gated by voltage-dependent channel blockade by intracellular
Mg2+; slow inactivation due to Ca2+-dependent calmodulin binding;
phosphorylation by PKC inhibits Ca2+-calmodulin binding and slow inactivation;
upregulated by 1,25-dihydroxyvitamin D3
Comments:
TRPA (ankyrin) family
Agents activating TRPA1 in a covalent manner are thiol reactive
electrophiles that bind to cysteine and lysine residues within the
cytoplasmic domain of the channel [149, 250]. TRPA1 is activated
by a wide range of endogenous and exogenous compounds and
only a few representative examples are mentioned in the table:
an exhaustive listing can be found in [16]. In addition, TRPA1 is
potently activated by intracellular zinc (EC50 = 8 nM) [10, 156].
TRPM (melastatin) family
Ca2+ activates all splice variants of TRPM2, but other activa-
tors listed are effective only at the full length isoform [96].
Inhibition of TRPM2 by clotrimazole, miconazole, econazole,
ﬂufenamic acid is largely irreversible. TRPM4 exists as multi-
ple spice variants: data listed are for TRPM4b. The sensitivity
of TRPM4b and TRPM5 to activation by [Ca2+]i demonstrates a
pronounced and time-dependent reduction following excision of
inside-out membrane patches [418]. The V½ for activation of
TRPM4 and TRPM5 demonstrates a pronounced negative shift
with increasing temperature. Activation of TRPM8 by depolariza-
tion is strongly temperature-dependent via a channel-closing rate
that decreases with decreasing temperature. The V½ is shifted in
the hyperpolarizing direction both by decreasing temperature and
by exogenous agonists, such as (-)-menthol [423] whereas antago-
nists produce depolarizing shifts in V½ [276]. The V½ for the native
channel is far more positive than that of heterologously expressed
TRPM8 [276]. It should be noted that (-)-menthol and structurally
related compounds can elicit release of Ca2+ from the endoplasmic
reticulum independent of activation of TRPM8 [254]. Intracellu-
lar pH modulates activation of TRPM8 by cold and icilin, but not
(-)-menthol [9].
TRPML (mucolipin) family
Data in the table are for TRPML proteins mutated (i.e TRPML1Va,
TRPML2Va and TRPML3Va) at loci equivalent to TRPML3 A419P to
allow plasma membrane expression when expressed in HEK-293
cells and subsequent characterisation by patch-clamp recording
[94, 123, 191, 281, 462]. Data for wild type TRPML3 are also tab-
ulated [191, 192, 281, 462]. It should be noted that alternative
methodologies, particularly in the case of TRPML1, have resulted
in channels with differing biophysical characteristics (reviewed by
[336]).
TRPP (polycystin) family
Data in the table are extracted from [79, 89] and [370]. Broadly
similar single channel conductance, mono- and di-valent cation
selectivity and sensitivity to blockers are observed for TRPP2 co-
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expressed with TRPP1 [88]. Ca2+, Ba2+ and Sr2+ permeate TRPP3,
but reduce inward currents carried by Na+. Mg2+ is largely imper-
meant and exerts a voltage dependent inhibition that increases
with hyperpolarization.
TRPV (vanilloid) family
Activation of TRPV1 by depolarisation is strongly temperature-
dependent via a channel opening rate that increases with increas-
ing temperature. The V½ is shifted in the hyperpolarizing di-
rection both by increasing temperature and by exogenous ago-
nists [423]. The sensitivity of TRPV4 to heat, but not 4α-PDD
is lost upon patch excision. TRPV4 is activated by anandamide
and arachidonic acid following P450 epoxygenase-dependent
metabolism to 5,6-epoxyeicosatrienoic acid (reviewed by [296]).
Activation of TRPV4 by cell swelling, but not heat, or phorbol es-
ters, is mediated via the formation of epoxyeicosatrieonic acids.
Phorbol esters bind directly to TRPV4. TRPV5 preferentially con-
ducts Ca2+ under physiological conditions, but in the absence of
extracellular Ca2+, conducts monovalent cations. Single chan-
nel conductances listed for TRPV5 and TRPV6 were determined in
divalent cation-free extracellular solution. Ca2+-induced inacti-
vation occurs at hyperpolarized potentials when Ca2+ is present
extracellularly. Single channel events cannot be resolved (proba-
bly due to greatly reduced conductance) in the presence of extra-
cellular divalent cations. Measurements of PCa/PNa for TRPV5 and
TRPV6 are dependent upon ionic conditions due to anomalous
mole fraction behaviour. Blockade of TRPV5 and TRPV6 by extra-
cellular Mg2+ is voltage-dependent. Intracellular Mg2+ also exerts
a voltage dependent block that is alleviated by hyperpolarization
and contributes to the time-dependent activation and deactiva-
tion of TRPV6 mediated monovalent cation currents. TRPV5 and
TRPV6 differ in their kinetics of Ca2+-dependent inactivation and
recovery from inactivation. TRPV5 and TRPV6 function as homo-
and hetero-tetramers.
Further reading on Transient Receptor Potential channels
Aghazadeh Tabrizi M et al. (2017) Medicinal Chemistry, Pharmacology, and Clinical Implications
of TRPV1 Receptor Antagonists. Med Res Rev 37: 936-983 [PMID:27976413]
Basso L et al. (2017) Transient Receptor Potential Channels in neuropathic pain. Curr Opin Pharma-
col 32: 9-15 [PMID:27835802]
Ciardo MG et al. (2017) Lipids as central modulators of sensory TRP channels. Biochim Biophys Acta
1859: 1615-1628 [PMID:28432033]
Clapham DE et al. (2003) International Union of Pharmacology. XLIII. Compendium of
voltage-gated ion channels: transient receptor potential channels. Pharmacol Rev 55: 591-6
[PMID:14657417]
Diaz-Franulic I et al. (2016) Allosterism and Structure in Thermally Activated Transient Receptor
Potential Channels. Annu Rev Biophys 45: 371-98 [PMID:27297398]
Grace MS et al. (2017) Modulation of the TRPV4 ion channel as a therapeutic target for disease.
Pharmacol Ther [PMID:28202366]
Grayson TH et al. (2017) Transient receptor potential canonical type 3 channels: Interactions, role
and relevance - A vascular focus. Pharmacol Ther 174: 79-96 [PMID:28223224]
Kashio M et al. (2017) The TRPM2 channel: a thermo-sensitive metabolic sensor. Channels (Austin)
0 [PMID:28633002]
Wu LJ et al. (2010) International Union of Basic and Clinical Pharmacology. LXXVI. Cur-
rent progress in the mammalian TRP ion channel family. Pharmacol Rev 62: 381-404
[PMID:20716668]
Zierler S et al. (2017) TRPM channels as potential therapeutic targets against pro-inﬂammatory
diseases. Cell Calcium [PMID:28549569]
Voltage-gated calcium channels
Voltage-gated ion channels → Voltage-gated calcium channels
Overview: Calcium (Ca2+) channels are voltage-gated ion chan-
nels present in the membrane of most excitable cells. The nomen-
clature for Ca2+channels was proposed by [101] and approved
by the NC-IUPHAR Subcommittee on Ca2+ channels [54].
Ca2+ channels form hetero-oligomeric complexes. The α1 sub-
unit is pore-forming and provides the binding site(s) for prac-
tically all agonists and antagonists. The 10 cloned α1-subunits
can be grouped into three families: (1) the high-voltage acti-
vated dihydropyridine-sensitive (L-type, CaV1.x) channels; (2)
the high-voltage activated dihydropyridine-insensitive (CaV2.x)
channels and (3) the low-voltage-activated (T-type, CaV3.x) chan-
nels. Each α1 subunit has four homologous repeats (I–IV), each
repeat having six transmembrane domains and a pore-forming
region between transmembrane domains S5 and S6. Gating
is thought to be associated with the membrane-spanning S4
segment, which contains highly conserved positive charges.
Many of the α1-subunit genes give rise to alternatively spliced
products. At least for high-voltage activated channels, it is likely
that native channels comprise co-assemblies of α1, β and α2–δ
subunits. The γ subunits have not been proven to associate with
channels other than the α1s skeletal muscle Cav1.1 channel. The
α2–δ1 and α2–δ2 subunits bind gabapentin and pregabalin.
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Nomenclature Cav1.1 Cav1.2 Cav1.3 Cav1.4
HGNC, UniProt CACNA1S, Q13698 CACNA1C, Q13936 CACNA1D, Q01668 CACNA1F, O60840
Activators FPL64176 (pEC50 ∼7.8), (-)-(S)-BayK8644
(pEC50 ∼7.8)
(-)-(S)-BayK8644 (pEC50 ∼7.8), FPL64176
Concentration range: 1×10−6M-5×10−6M
[243] – Rat
FPL64176 (pEC50 ∼7.8), (-)-(S)-BayK8644
(pEC50 ∼7.8)
(-)-(S)-BayK8644 (pEC50 ∼7.8)
Gating inhibitors nifedipine (pIC50 6.3) Concentration
range: 1×10−7M-1×10−4M [voltage
dependent -90mV] [215] – Rat,
nimodipine (pIC50 ∼6) [-70mV],
nitrendipine (pIC50 6) [-80mV] [25] – Rat
nifedipine (pIC50 7.7) [-80mV] [329] – Rat,
nimodipine (pIC50 6.8) [-80mV] [465] –
Rat, nitrendipine (pIC50 6) [-80mV] [465] –
Rat
nitrendipine (pIC50 8.4) [373], nifedipine
(pIC50 7.7) [373], nimodipine (pIC50
5.7–6.6) [-80mV – -40mV] [357, 465] –
Rat
nifedipine (pIC50 6) [-100mV] [267],
nimodipine (pIC50 ∼6) [-70mV],
nitrendipine (pIC50 ∼6) [-70mV]
Selective gating inhibitors – – – –
Channel blockers diltiazem, verapamil diltiazem, verapamil verapamil diltiazem (pIC50 4) [-80mV] [21] –
Mouse, verapamil Concentration
range: 1×10−4M [-80mV] [21] –
Mouse
Sub/family-selective channel
blockers
calciseptine calciseptine – –
Functional Characteristics L-type calcium current: High
voltage-activated, slow voltage
dependent inactivation
L-type calcium current: High
voltage-activated, slow voltage-dependent
inactivation, rapid calcium-dependent
inactivation
L-type calcium current: Voltage-activated,
slow voltage-dependent inactivation,
more rapid calcium-dependent
inactivation
L-type calcium current: Moderate
voltage-activated, slow
voltage-dependent inactivation
Comments – – Cav1.3 activates more negative potentials
than Cav1.2 and is incompletely inhibited
by dihydropyridine antagonists.
Cav1.4 is less sensitive to
dihydropyridine antagonists than
other Cav1 channels
Nomenclature Cav2.1 Cav2.2 Cav2.3
HGNC, UniProt CACNA1A, O00555 CACNA1B, Q00975 CACNA1E, Q15878
Selective gating inhibitors ω-agatoxin IVA (P current component: Kd = ˜2nM, Q
component Kd= >100nM) (pIC50 7–8.7) [-100mV –
-90mV] [38, 270] – Rat, ω-agatoxin IVB (pKd 8.5)
[-80mV] [4] – Rat
– SNX482 (pIC50 7.5–8) [physiological voltage] [286]
Channel blockers – – Ni2+ (pIC50 4.6) [-90mV] [448]
Sub/family-selective channel
blockers
ω-conotoxin MVIIC (pIC50 8.2–9.2) Concentration
range: 2×10−6M-5×10−6M [physiological voltage]
[229] – Rat
ω-conotoxin GVIA (pIC50 10.4) [-80mV] [229] – Rat,
ω-conotoxin MVIIC (pIC50 6.1–8.5) [-80mV] [148, 229,
264] – Rat
–
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Nomenclature Cav2.1 Cav2.2 Cav2.3
Functional Characteristics P/Q-type calcium current: Moderate voltage-activated,
moderate voltage-dependent inactivation
N-type calcium current: High voltage-activated,
moderate voltage-dependent inactivation
R-type calcium current: Moderate voltage-activated,
fast voltage-dependent inactivation
Nomenclature Cav3.1 Cav3.2 Cav3.3
HGNC, UniProt CACNA1G, O43497 CACNA1H, O95180 CACNA1I, Q9P0X4
Gating inhibitors kurtoxin (pIC50 7.3–7.8) [-90mV] [63, 371] – Rat kurtoxin (pIC50 7.3–7.6) [-90mV] [63, 371] – Rat –
Channel blockers mibefradil (pIC50 6–6.6) [-110mV – -100mV] [261],
Ni2+ (pIC50 3.6–3.8) [voltage dependent -90mV] [218]
– Rat
mibefradil (pIC50 5.9–7.2) [-110mV – -80mV] [261],
Ni2+ (pIC50 4.9–5.2) [voltage dependent -90mV] [218]
mibefradil (pIC50 5.8) [-110mV] [261], Ni2+ (pIC50
3.7–4.1) [voltage dependent -90mV] [218] – Rat
Functional Characteristics T-type calcium current: Low voltage-activated, fast
voltage-dependent inactivation
T-type calcium current: Low voltage-activated, fast
voltage-dependent inactivation
T-type calcium current: Low voltage-activated,
moderate voltage-dependent inactivation
Comments: In many cell types, P and Q current components cannot be adequately separated and many researchers in the ﬁeld have adopted the terminology ‘P/Q-type’ current when referring to either
component. Both of these physiologically deﬁned current types are conducted by alternative forms of Cav2.1. Ziconotide (a synthetic peptide equivalent to ω-conotoxin MVIIA) has been approved for
the treatment of chronic pain [447].
Further reading on Voltage-gated calcium channels
Catterall WA et al. (2015) Structural Basis for Pharmacology of Voltage-Gated Sodium and Calcium
Channels. Mol Pharmacol 88: 141-50 [PMID:25848093]
Catterall WA et al. (2005) International Union of Pharmacology. XLVIII. Nomenclature and
structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 57: 411-25
[PMID:16382099]
Catterall WA et al. (2015) Deciphering voltage-gated Na(+) and Ca(2+) channels by studying
prokaryotic ancestors. Trends Biochem Sci 40: 526-34 [PMID:26254514]
Dolphin AC. (2016) Voltage-gated calcium channels and their auxiliary subunits: physiology and
pathophysiology and pharmacology. J Physiol 594: 5369-90 [PMID:27273705]
Huang J et al. (2017) Regulation of voltage gated calcium channels by GPCRs and post-translational
modiﬁcation. Curr Opin Pharmacol 32: 1-8 [PMID:27768908]
Ortner NJ et al. (2016) L-type calcium channels as drug targets in CNS disorders. Channels (Austin)
10: 7-13 [PMID:26039257]
Rougier JS et al. (2016) Cardiac voltage-gated calcium channel macromolecular complexes. Biochim
Biophys Acta 1863: 1806-12 [PMID:26707467]
Zamponi GW. (2016) Targeting voltage-gated calcium channels in neurological and psychiatric dis-
eases. Nat Rev Drug Discov 15: 19-34 [PMID:26542451]
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Voltage-gated proton channel
Voltage-gated ion channels → Voltage-gated proton channel
Overview: The voltage-gated proton channel (provisionally de-
noted Hv1) is a putative 4TM proton-selective channel gated by
membrane depolarization and which is sensitive to the transmem-
brane pH gradient [49, 84, 85, 346, 362]. The structure of Hv1
is homologous to the voltage sensing domain (VSD) of the su-
perfamily of voltage-gated ion channels (i.e. segments S1 to S4)
and contains no discernable pore region [346, 362]. Proton ﬂux
through Hv1 is instead most likely mediated by a water wire com-
pleted in a crevice of the protein when the voltage-sensing S4 helix
moves in response to a change in transmembrane potential [345,
453]. Hv1 expresses largely as a dimer mediated by intracellular
C-terminal coiled-coil interactions [231] but individual promoters
nonetheless support gated H+ ﬂux via separate conduction path-
ways [203, 221, 327, 412]. Within dimeric structures, the two pro-
tomers do not function independently, but display co-operative
interactions during gating resulting in increased voltage sensitiv-
ity, but slower activation, of the dimeric,versus monomeric, com-
plexes [121, 413].
Nomenclature Hv1
HGNC, UniProt HVCN1, Q96D96
Channel blockers Zn2+ (pIC50 ∼5.7–6.3), Cd2+ (pIC50 ∼5)
Functional Characteristics Activated by membrane depolarization mediating macroscopic currents with time-, voltage- and pH-dependence; outwardly rectifying; voltage dependent kinetics with
relatively slow current activation sensitive to extracellular pH and temperature, relatively fast deactivation; voltage threshold for current activation determined by pH gradient
(pH = pHo -pHi) across the membrane
Comments: The voltage threshold (Vthr) for activation of Hv1
is not ﬁxed but is set by the pH gradient across the membrane
such that Vthr is positive to the Nernst potential for H
+, which
ensures that only outwardly directed ﬂux of H+ occurs under phys-
iological conditions [49, 84, 85]. Phosphorylation of Hv1 within
the N-terminal domain by PKC enhances the gating of the chan-
nel [274]. Tabulated IC50 values for Zn
2+ and Cd2+ are for het-
erologously expressed human and mouse Hv1 [346, 362]. Zn2+
is not a conventional pore blocker, but is coordinated by two,
or more, external protonation sites involving histamine residues
[346]. Zn2+ binding may occur at the dimer interface between
pairs of histamine residues from both monomers where it may
interfere with channel opening [275]. Mouse knockout stud-
ies demonstrate that Hv1 participates in charge compensation
in granulocytes during the respiratory burst of NADPH oxidase-
dependent reactive oxygen species production that assists in the
clearance of bacterial pathogens [347]. Additional physiological
functions of Hv1 are reviewed by [49].
Further reading on Voltage-gated proton channel
Castillo K et al. (2015) Voltage-gated proton (H(v)1) channels, a singular voltage sensing domain.
FEBS Lett 589: 3471-8 [PMID:26296320]
DeCoursey TE. (2015) The Voltage-Gated Proton Channel: A Riddle, Wrapped in a Mystery, inside
an Enigma. Biochemistry 54: 3250-68 [PMID:25964989]
DeCoursey TE. (2013) Voltage-gated proton channels: molecular biology, physiology, and patho-
physiology of the H(V) family. Physiol Rev 93: 599-652 [PMID:23589829]
Fernandez A et al. (2016) Pharmacological Modulation of Proton Channel Hv1 in Cancer Therapy:
Future Perspectives. Mol Pharmacol 90: 385-402 [PMID:27260771]
Okamura Y et al. (2015) Gating mechanisms of voltage-gated proton channels. Annu Rev Biochem
84: 685-709 [PMID:26034892]
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Voltage-gated sodium channels
Voltage-gated ion channels → Voltage-gated sodium channels
Overview: Sodium channels are voltage-gated sodium-selective
ion channels present in the membrane of most excitable cells.
Sodium channels comprise of one pore-forming α subunit, which
may be associated with either one or two β subunits [169]. α-
Subunits consist of four homologous domains (I–IV), each con-
taining six transmembrane segments (S1–S6) and a pore-forming
loop. The positively charged fourth transmembrane segment (S4)
acts as a voltage sensor and is involved in channel gating. The
crystal structure of the bacterial NavAb channel has revealed a
number of novel structural features compared to earlier potassium
channel structures including a short selectivity ﬁlter with ion se-
lectivity determined by interactions with glutamate side chains
[316]. Interestingly, the pore region is penetrated by fatty acyl
chains that extend into the central cavity whichmay allow the en-
try of small, hydrophobic pore-blocking drugs [316]. Auxiliary β1,
β2, β3 and β4 subunits consist of a large extracellular N-terminal
domain, a single transmembrane segment and a shorter cytoplas-
mic domain.
The nomenclature for sodium channels was proposed
by Goldin et al., (2000) [119] and approved by the
NC-IUPHAR Subcommittee on sodium channels (Catter-
all et al., 2005, [52]).
Nomenclature Nav1.1 Nav1.2 Nav1.3 Nav1.4
HGNC, UniProt SCN1A, P35498 SCN2A, Q99250 SCN3A, Q9NY46 SCN4A, P35499
Sub/family-selective
activators
batrachotoxin, veratridine batrachotoxin (pKd 9.1) [physiological voltage]
[237] – Rat, veratridine (pKd 5.2) [physiological
voltage] [53] – Rat
batrachotoxin,
veratridine
batrachotoxin Concentration range: 5×10−6M [-100mV]
[438] – Rat, veratridine Concentration range: 2×10−4M
[-100mV] [438] – Rat
Channel blockers tetrodotoxin (pKd 8) [-100mV]
[378] – Rat
– – –
Sub/family-selective channel
blockers
Hm1a [306] – Rat, saxitoxin saxitoxin (pIC50 8.8) [-120mV] [40] – Rat,
tetrodotoxin (pIC50 8) [-120mV] [40] – Rat,
lacosamide (pIC50 4.5) [-80mV] [1] – Rat
tetrodotoxin (pIC50 8.4)
[60], saxitoxin
saxitoxin (pIC50 8.4) [-100mV] [324] – Rat, tetrodotoxin
(pIC50 7.6) [-120mV] [56], μ-conotoxin GIIIA (pIC50 5.9)
[-100mV] [56]
Functional Characteristics Activation V0.5 = -20 mV. Fast
inactivation (τ = 0.7 ms for peak
sodium current).
Activation V0.5 = -24 mV. Fast inactivation (τ = 0.8
ms for peak sodium current).
Activation V0.5 = -24
mV. Fast inactivation
(0.8 ms)
Activation V0.5 = -30 mV. Fast inactivation (0.6 ms)
Nomenclature Nav1.5 Nav1.6 Nav1.7 Nav1.8 Nav1.9
HGNC, UniProt SCN5A, Q14524 SCN8A, Q9UQD0 SCN9A, Q15858 SCN10A, Q9Y5Y9 SCN11A, Q9UI33
Sub/family-selective
activators
batrachotoxin (pKd 7.6) [physiological voltage]
[368] – Rat, veratridine (pEC50 6.3) [-30mV]
[433] – Rat
batrachotoxin, veratridine batrachotoxin, veratridine – –
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(continued)
Nomenclature Nav1.5 Nav1.6 Nav1.7 Nav1.8 Nav1.9
Sub/family-selective
channel blockers
tetrodotoxin (pKd 5.8) [-80mV] [74, 477] – Rat tetrodotoxin (pIC50 9)
[-130mV] [91] – Rat,
saxitoxin
tetrodotoxin (pIC50 7.6) [-100mV]
[199], saxitoxin (pIC50 6.2) [431]
tetrodotoxin (pIC50 4.2)
[-60mV] [5] – Rat
tetrodotoxin (pIC50 4.4)
[-120mV] [76] – Rat
Selective channel blockers – – – PF-01247324 (pIC50 6.7)
[voltage dependent] [317]
–
Functional Characteristics Activation V0.5 = -26 mV. Fast inactivation (τ = 1
ms for peak sodium current).
Activation V0.5 = -29 mV.
Fast inactivation (1 ms)
Activation V0.5 = -27 mV. Fast
inactivation (0.5 ms)
Activation V0.5 = -16 mV.
Inactivation (6 ms)
Activation V0.5 = -32 mV.
Slow inactivation (16 ms)
Comments: Sodium channels are also blocked by local anaes-
thetic agents, antiarrythmic drugs and antiepileptic drugs. In gen-
eral, these drugs are not highly selective among channel subtypes.
There are two clear functional ﬁngerprints for distinguishing dif-
ferent subtypes. These are sensitivity to tetrodotoxin (NaV1.5,
NaV1.8 and NaV1.9 are much less sensitive to block) and rate of
fast inactivation (NaV1.8 and particularly NaV1.9 inactivate more
slowly). All sodium channels also have a slow inactivation process
that is engaged during long depolarizations (>100 msec) or repet-
itive trains of stimuli. All sodium channel subtypes are blocked by
intracellular QX-314.
Further reading on Voltage-gated sodium channels
Catterall WA et al. (2005) International Union of Pharmacology. XLVII. Nomenclature and
structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 57: 397-409
[PMID:16382098]
Catterall WA et al. (2017) The chemical basis for electrical signaling. Nat Chem Biol 13: 455-463
[PMID:28406893]
Deuis JR et al. (2017) The pharmacology of voltage-gated sodium channel activators. Neuropharma-
cology [PMID:28416444]
Kanellopoulos AH et al. (2016) Voltage-gated sodium channels and pain-related disorders. Clin Sci
(Lond) 130: 2257-2265 [PMID:27815510]
Terragni B et al. (2017) Post-translational dysfunctions in channelopathies of the nervous system.
Neuropharmacology [PMID:28571716]
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